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A B S T R A C T
Background
Vitamins and minerals have many functions in the nervous system which are important for brain health. It has been suggested that various
di%erent vitamin and mineral supplements might be useful in maintaining cognitive function and delaying the onset of dementia. In this
review, we sought to examine the evidence for this in people who already had mild cognitive impairment (MCI).
Objectives
To evaluate the e%ects of vitamin and mineral supplementation on cognitive function and the incidence of dementia in people with mild
cognitive impairment.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group’s (CDCIG) specialised register, as well as MEDLINE, Embase,
PsycINFO, CENTRAL, CINAHL, LILACs, Web of Science Core Collection, ClinicalTrials.gov, and the WHO Portal/ICTRP, from inception to 25
January 2018.
Selection criteria
We included randomised or quasi-randomised, placebo-controlled trials which evaluated orally administered vitamin or mineral
supplements in participants with a diagnosis of mild cognitive impairment and which assessed the incidence of dementia or cognitive
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outcomes, or both. We were interested in studies applicable to the general population of older people and therefore excluded studies in
which participants had severe vitamin or mineral deficiencies.
Data collection and analysis
We sought data on our primary outcomes of dementia incidence and overall cognitive function and on secondary outcomes of episodic
memory, executive function, speed of processing, quality of life, functional performance, clinical global impression, adverse events, and
mortality. We conducted data collection and analysis according to standard Cochrane systematic review methods. We assessed the risk of
bias of included studies using the Cochrane 'Risk of bias' assessment tool. We grouped vitamins and minerals according to their putative
mechanism of action and, where we considered it to be clinically appropriate, we pooled data using random-e%ects methods. We used
GRADE methods to assess the overall quality of evidence for each comparison and outcome.
Main results
We included five trials with 879 participants which investigated B vitamin supplements. In four trials, the intervention was a combination
of vitamins B6, B12, and folic acid; in one, it was folic acid only. Doses varied. We considered there to be some risks of performance
and attrition bias and of selective outcome reporting among these trials. Our primary e%icacy outcomes were the incidence of dementia
and scores on measures of overall cognitive function. None of the trials reported the incidence of dementia and the evidence on overall
cognitive function was of very low-quality. There was probably little or no e%ect of B vitamins taken for six to 24 months on episodic
memory, executive function, speed of processing, or quality of life. The evidence on our other secondary clinical outcomes, including
harms, was very sparse or very low-quality. There was evidence from one study that there may be a slower rate of brain atrophy over two
years in participants taking B vitamins. The same study reported subgroup analyses based on the level of serum homocysteine (tHcy) at
baseline and found evidence that B vitamins may improve episodic memory in those with tHcy above the median at baseline.
We included one trial (n = 516) of vitamin E supplementation. Vitamin E was given as 1000 IU of alpha-tocopherol twice daily. We considered
this trial to be at risk of attrition and selective reporting bias. There was probably no e%ect of vitamin E on the probability of progression
from MCI to Alzheimer's dementia over three years (HR 1.02; 95% CI 0.74 to 1.41; n = 516; 1 study, moderate-quality evidence). There was
also no evidence of an e%ect at intermediate time points. The available data did not allow us to conduct analyses, but the authors reported
no significant e%ect of three years of supplementation with vitamin E on overall cognitive function, episodic memory, speed of processing,
clinical global impression, functional performance, adverse events, or mortality (five deaths in each group). We considered this to be low-
quality evidence.
We included one trial (n = 256) of combined vitamin E and vitamin C supplementation and one trial (n = 26) of supplementation with
chromium picolinate. In both cases, there was a single eligible cognitive outcome, but we considered the evidence to be very low-quality
and so could not be sure of any e%ects.
Authors' conclusions
The evidence on vitamin and mineral supplements as treatments for MCI is very limited. Three years of treatment with high-dose vitamin E
probably does not reduce the risk of progression to dementia, but we have no data on this outcome for other supplements. Only B vitamins
have been assessed in more than one RCT. There is no evidence for beneficial e%ects on cognition of supplementation with B vitamins for
six to 24 months. Evidence from a single study of a reduced rate of brain atrophy in participants taking vitamin B and a beneficial e%ect of
vitamin B on episodic memory in those with higher tHcy at baseline warrants attempted replication.
P L A I N   L A N G U A G E   S U M M A R Y
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive
impairment
Review question
This review investigated whether people with mild cognitive impairment can reduce their risk of developing dementia, or can prevent their
memory or other thinking skills from deteriorating further, by taking vitamin or mineral supplements.
Background
Slight changes in memory and thinking skills are common as people get older. When these changes are worse than can be expected in
normal ageing, but are not bad enough to make a person's usual activities di%icult to manage, then the person is said to have mild cognitive
impairment (MCI). People with MCI are at increased risk of developing dementia in the future.
Vitamins and minerals are naturally occurring substances which are needed in the diet to maintain health. They have lots of di%erent
functions in the body and many are essential to keep the brain working properly. It has been suggested that supplementing a person's
normal diet with extra doses of these vitamins or minerals might help to maintain thinking skills or prevent dementia.
Study characteristics
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We found eight randomised controlled trials (RCTs), which investigated four di%erent types of vitamin or mineral pills by comparing them
to a placebo (a dummy pill). The vitamins tested were B vitamins (vitamin B6, vitamin B12 and folic acid), vitamin E, and vitamin E and C
given together. The only mineral tested was chromium.
Key results and quality of the evidence
Vitamin B combination versus placebo
Five trials with a total of 879 participants compared B vitamins with placebo. Four used combinations of vitamin B6, vitamin B12, and folic
acid; one small study tested folic acid on its own. None of these studies reported whether or not participants developed dementia. These
studies did not find that memory or thinking skills di%ered between the group of people who took vitamin B supplements and those who
took placebo aSer treatment lasting six months to two years. Our confidence in the results on di%erent tests used in the studies varied from
moderate to very low. Two years of vitamin B supplements did seem to help memory in a small subgroup of participants in one study who
could be identified by a particular blood test at the start of the trial. One study found that there was probably no e%ect on participants'
quality of life. One study scanned the brains of some participants and reported that B vitamins may slow the rate of brain shrinkage.
Harmful e%ects and deaths were reported in very few participants and we cannot conclude whether or not there are harms from taking
these or similar combinations of B vitamins.
Vitamin E versus placebo.
One study with 516 participants compared a relatively high dose of vitamin E (2000 IU a day) to placebo in people who were also taking a
multivitamin containing 15 IU of vitamin E (the daily requirement for vitamin E is approximately 30 IU). The risk of developing dementia
due to Alzheimer’s disease (the commonest form of dementia) is probably not a%ected by three years of treatment with high-dose vitamin
E. The quality of the evidence for other outcomes was lower, but there may also be no e%ect of this dose of vitamin E on specific memory
or thinking skills or on how well people could manage their daily activities.
Vitamin E and C versus placebo
One study with 256 participants compared a combination of vitamins C and E with placebo. It found no e%ect on overall memory and
thinking skills, but we had little confidence in this result because of the quality of the evidence.
Chromium picolinate versus placebo
Only one very small study with 26 participants investigated the e%ect of chromium supplements. This study was too small for us to be able
to draw any conclusions.
Conclusions
The amount and quality of research evidence about vitamin and mineral supplements for treating MCI in people without nutritional
deficiency is limited. At the moment, it is not possible to identify any supplements which can reduce the risk of people with MCI developing
dementia or which can e%ectively treat their symptoms. More research is needed before we can answer our review question.
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Summary of findings for the main comparison.   B vitamins compared to placebo for MCI
B vitamins compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: B vitamins (B6, B12, folic acid)
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo Risk with B vitamins
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Incidence of dementia - not measured - - - -  
Overall cognitive function
assessed with: MMSE
Scale from: 0 to 30
follow-up: range 6 months to 24 months
MD with B vitamins was 0.44 MMSE points higher
(0.23 lower to 1.12 higher) than with placebo *
488
(3 RCTs)
⊕⊝⊝⊝
VERY LOW 1 2 3
Due to the very low-quality of the
evidence, we cannot be sure of any
effect of B vitamins on overall cog-
nitive function.
* 2 studies reported final score; 1
study reported change from base-
line. From the 2 studies (n=150)
which reported final scores, the
mean MMSE with placebo was
26.97 points.
Episodic memory
assessed with: various word list recall instru-
mentsa
follow-up: range 6 months to 24 months
SMD with B vitamins was 0.09 higher
(0.1 lower to 0.29 higher) than with placebo
397
(3 RCTs)
⊕⊕⊕⊝
MODERATE 3
B vitamins probably resulted in
little to no difference in episodic
memory.
Executive function
assessed with: various instrumentsb
follow-up: range 6 months to 24 months
SMD with B vitamins was 0.03 higher
(0.23 lower to 0.29 higher) than with placebo
392
(3 RCTs)
⊕⊕⊕⊝
MODERATE 4
B vitamins probably resulted in lit-
tle to no difference in executive
function.
Speed of processing
assessed with: various instrumentsc
follow-up: range 6 months to 24 months
SMD with B vitamins was 0.04 higher
(0.26 lower to 0.34 higher) than with placebo
173
(2 RCTs)
⊕⊕⊕⊝
MODERATE 4
B vitamins probably resulted in lit-
tle to no difference in speed of pro-
cessing.
Quality of life
assessed with: D-QOL
The mean quality of
life was 3.5 points
MD 0 points 138
(1 RCT)
⊕⊕⊕⊝
MODERATE 5
B vitamins probably resulted in lit-
tle to no difference in quality of life.
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Scale from: 1 to 5
follow-up: 12 months
(0.1 lower to 0.1 high-
er)
Mortality - not reported Reported by only one study (2/133 died in vita-
min B group, 0/133 died in placebo group).
- -  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
MD: Mean difference; SMD: Standardised mean difference; CI: Confidence interval; RR: Risk ratio; OR: Odds ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded due to risk of bias. One study was at high risk of performance bias and at unclear risk of selection and detection bias.
2 Downgraded due to inconsistency. I2 = 87%.
3 Downgraded due to imprecision. 95% CI included little or no e%ect and small benefit of B vitamins.
4 Downgraded due to imprecision. 95% CI included small e%ects in either direction.
5 Downgraded due to imprecision. Result derived from one small study.
aEpisodic memory assessed with Hopkins Verbal Learning Test, word learning and the Auditory Verbal Learning Test.
bExecutive function assessed with CLOX, the Stroop test, and the Frontal Assessment Battery.
cSpeed of processing assessed with Trail-making Test A, digit cancellation, and the Digit-Symbol Substitution Test.
CLOX: Clock drawing executive test
D-QOL: Dementia quality of life questionnaire
MCI: Mild cognitive impairment
MMSE: Mini-mental state examination
 
 
Summary of findings 2.   Vitamin E compared to placebo for MCI
Vitamin E compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: vitamin E
Comparison: placebo
Outcomes Impact № of partici-
pants
Certainty of the
evidence
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(studies) (GRADE)
Incidence of dementia due to Alzheimer's disease
follow-up: 36 months
76 cases in vitamin E group and 73 cases in placebo group (HR
1.02, 95% CI 0.74 to 1.41)
516
(1 RCT)
⊕⊕⊕⊝
MODERATE 1
Overall cognitive functioning
assessed with: MMSE and ADAS-cog
follow-up: 36 months
Single study reported no significant difference between groups in
changes from baseline of MMSE or ADAS-cog. Sample sizes not re-
ported.
(1 RCT) ⊕⊕⊝⊝
LOW 2 3
Episodic memory
assessed with: z-score incorporating various instrumentsa
follow-up: 36 months
Single study reported no significant difference between groups.
Sample size not reported.
(1 RCT) ⊕⊕⊝⊝
LOW 2 3
Executive functioning
assessed with: z-score incorporating various instrumentsb
follow-up: 36 months
Single study reported no significant difference between groups.
Sample size not reported.
(1 RCT) ⊕⊕⊝⊝
LOW 2 3
Quality of life - not measured   - -
Mortality No significant difference in deaths reported between vitamin E,
donepezil, and placebo groups during double-blind phase of trial.
(1 RCT) -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded due to imprecision. 95% CI around hazard ratio included possible e%ect in both directions.
2 Downgraded due to imprecision. Single study. Sample size for this outcome not reported.
3 Downgraded due to risk of bias. High risk of bias due to incomplete outcome data and selective reporting.
aEpisodic memory assessed using standardised composite z-score incorporating ADAS immediate and delayed word-recall scores and the New York University immediate and
delayed paragraph-recall scores.
bExecutive function assessed using standardised composite z-score incorporating the digits-backward test, Symbol Digit Modalities Test, and number-cancellation test.
ADAS-cog: Alzheimer's Disease Assessment Scale - cognitive
MCI: Mild cognitive impairment
MMSE: Mini-mental state examination
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Summary of findings 3.   Vitamin E + vitamin C compared to placebo for MCI
Vitamin E + vitamin C compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: vitamin E + vitamin C
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo Risk with vitamin E
+ vitamin C
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Incidence of dementia - not measured - - - -  
Overall cognitive function
assessed with: MMSE (Iranian version)
Scale from: 0 to 30
follow-up: 12 months
The mean overall
cognitive function
was 26.6 points
MD 0.23 points high-
er
(0.25 lower to 0.71
higher)
256
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2 3
Due to very low-quality evi-
dence, we cannot be sure of
any effect of vitamin C + vit-
amin E on overall cognitive
function.
Episodic memory - not measured - - - -  
Executive function - not measured - - - -  
Speed of processing - not measured - - - -  
Quality of life - not measured - - - -  
Mortality - not reported - - - -  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
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1 Downgraded due to risk of bias. Unclear risks of selection, performance, and attrition bias.
2 Downgraded due to indirectness. Inadequate definition of MCI.
3 Downgraded due to imprecision. Result from a single small study.
MCI: Mild cognitive impairment
MMSE: Mini-mental state examination
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B A C K G R O U N D
Description of the condition
Mild cognitive impairment and dementia
Prior to the onset of dementia, there can be a prodromal
(pre-symptomatic) stage which is oSen termed 'mild cognitive
impairment' (MCI). The category of MCI captures those individuals
whose cognitive deficits are beyond those typically seen in normal
ageing and who are at high risk of future dementia. Di%erent
criteria have been proposed to identify MCI, but, broadly speaking,
MCI of the amnestic subtype is a state where individuals have
subjective and objective memory impairment that is inconsistent
with age, but normal global cognitive functioning, and normal
performance in non-memory cognitive domains. The main focus
of these criteria is to detect memory problems due to prodromal
Alzheimer’s disease (AD). However, not all forms of MCI evolve into
AD dementia and, therefore, there have been calls for broader,
more inclusive criteria. In 2003, an International Working Group
(IWG) developed consensus criteria and expanded the definition
of MCI to include objective and subjective impairments in any
cognitive domain (Winblad 2004). The influential Petersen criteria
have been similarly extended (Petersen 2004). In recent years,
new criteria have been proposed for MCI due to AD, including
the National Institute on Aging-Alzheimer’s Association (NIA-AA)
criteria for preclinical/prodromal states (Albert 2011), updated NIA-
AA research criteria (Jack 2018), and updated versions of the IWG
criteria (Dubois 2014).
Dementia is a syndrome of cognitive and functional decline which
is usually progressive and which involves impairment in more
than one cognitive function, memory being the most commonly
a%ected in the early stages. Other higher cortical functions such
as orientation, comprehension, learning, language, and judgement
are also oSen a%ected. In most cases, the onset of dementia and
its subsequent progression is gradual. The cognitive deficits in
the early stages of the illness are relatively mild, but still have an
impact on the ability to perform some normal daily activities. As the
syndrome progresses, people with dementia eventually become
increasingly dependent on others for support with all activities of
daily living.
Types of MCI and dementia
There are numerous di%erent definitions of MCI, with di%erent
focus (e.g. nature of the neuropsychological impairment, such as
memory or non-memory (Matthews 2007); prevalence (Stephan
2007); and risk of progression to dementia (Matthews 2008). Further
subdivisions can be made depending on the suspected underlying
cause of the cognitive deficits (e.g. MCI due to AD and MCI
due to vascular disease, termed 'vascular cognitive impairment
no dementia' (VCIND)). Moreover, attempts have been made to
develop new criteria to capture even earlier preclinical states
including, for example, 'pre-MCI' that captures individuals with
impaired executive function and language, higher apathy scores,
and lower leS hippocampal volumes on brain imaging compared
to normal controls (Duara 2011). There is no standard definition of
MCI universally accepted for use in clinical trials (Stephan 2013),
but adaptations of the criteria suggested by Petersen are commonly
used (Petersen 1999).
Subtypes of dementia are distinguished by the underlying
pathology. The four most common subtypes are Alzheimer's
disease dementia (AD) (accounting for an estimated 60% to 70%
of all dementia cases); vascular dementia (VaD); dementia with
Lewy Bodies (DLB); and frontotemporal dementia (FTD). Accurate
diagnosis of the subtypes may be di%icult. Mixed pathology is
common, with more than 80% of cases having some features
of Alzheimer’s disease (Jellinger 2006; WHO 2012). However, the
proportion of dementia attributable to Alzheimer’s disease reduces
with age (Savva 2009).
Prevalence of MCI and dementia
In the UK Medical Research Council's population-based Cognitive
Function and Ageing Study (CFAS), when 18 di%erent definitions of
MCI were mapped, the range of prevalence estimates was found
to be highly variable (0.1% to 42.0%), and conversion rates to
dementia generally low (Stephan 2007). In general, prevalence and
conversion rates in specialist settings have been reported to be
higher than in population-based studies (adjusted conversion rate
from MCI to dementia 9.6% versus 4.9%) (Mitchell 2009).
The risk of dementia increases with age; according to a World
Health Organization (WHO) report, only 2% to 10% of cases start
before the age of 65 (WHO 2012). The same report estimated
that there were 35.6 million people with dementia in the world
in 2010, and that this figure would double every 20 years to
reach 65.7 million in 2030 (WHO 2012). However, there is a
degree of uncertainty about the expected increase in prevalence of
dementia. Recent research in the UK (Matthews 2013) and Denmark
(Christensen 2013) suggests that the age-specific prevalence of
dementia may be falling in developed countries, supporting the
idea that there may be modifiable risk factors. Nevertheless,
because of population ageing, the overall prevalence continues to
rise.
Risk factors
Generally, risk factors for dementia can be divided into modifiable
and non-modifiable factors. The non-modifiable risk factors
include age, genetic factors, family history, gender (females are
at higher risk), and Down syndrome. The modifiable factors are
smoking, high cholesterol, stroke, hypertension, lack of physical
activity, diabetes mellitus, obesity, and low educational level.
Among the non-modifiable risk factors, age has the greatest e%ect.
It has been calculated that in people older than 65, the risk of
AD (the commonest cause of dementia) doubles every five years
(Launer 1999; McCullagh 2001; van den Berg 2012; van der Flier
2005). A pooled analysis of four prospective studies in Europe
found the incidence rate of AD among people aged 90 and over to
be 63.5/1000 person-years (Launer 1999). Genetics plays a major
role in early onset AD, but a lesser role in the much commoner
late onset disease. Epidemiological evidence suggests that many
of the modifiable risk factors (diabetes, midlife obesity, midlife
hypertension, smoking, and physical inactivity) are risk factors for
both AD and vascular disease, including vascular dementia (The
World Alzheimer Report 2014; WHO 2012).
At present, there is no cure for any subtype of dementia,
but identifying and targeting modifiable risk factors may o%er
opportunities to modify its onset and course. Research has been
reported suggesting that cognitive stimulation, exercise, diet, and
the management of vascular risk factors such as hypertension,
diabetes, obesity, smoking, and physical inactivity may have
an important role in prevention of AD (Lindsay 2002; Lourida
2013; Norton 2014; Wilson 2002). There is also some evidence in
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support of vitamin supplementation as a preventive strategy. For
example, vitamin B12 and folate lower levels of homocysteine,
which is believed to be toxic to neurones. Protective e%ects of
vitamin D and vitamin E against AD have also been proposed
(Annweiler 2012; Dysken 2014; Llewellyn 2010). Many minerals
might have antioxidant properties and may also be beneficial in
protecting against oxidative stress and free radical damage. Hence,
an evaluation of the role of vitamins and minerals as protective
and preventive agents in cognitive impairment is warranted (see
Appendix 1).
Description of the intervention
This review focusses on RCTs investigating the e%ect of vitamin
and mineral supplementation for preventing dementia or delaying
cognitive decline in people with mild cognitive impairment.
Vitamins are organic compounds that are essential for the normal
physiological process in the body and play important roles in
growth and development (Kennedy 2011). Minerals are inorganic
elements that come from the earth; as nutrients, they have
similar essential roles in normal physiology (Centers for Disease
Control and Prevention 2014). All of these essential nutrients are
available naturally in food, although deficiencies can occur due
to inadequate dietary intake or a variety of disease states. Dietary
supplements are any consumed products that aim to provide
additional nutrients to those obtained from the usual diet.
How the intervention might work
Vitamins and minerals have multiple important roles in the
physiology of the human body at cellular and tissue levels. Putative
biological mechanisms for each are summarised briefly in Appendix
1.
There is a complex array of micronutrients which protect the
brain in a variety of ways, including protection against damaging
oxygen-free radicals, and which are important in neurogenesis,
gene expression, and enzyme and receptor control (Powell 2000).
Failure of these important systems appears to be implicated in
the occurrence of neural damage (van der SchaS 2013). Therefore,
ensuring adequate vitamin and mineral levels in the body might
enhance cognitive function.
Oxidative stress has been shown to be a damaging process
leading to an imbalance between oxygen-free radicals, and
the anti-oxidative defences and repair of oxidative damage to
proteins, lipids, RNA, and DNA (Halliwell 1992; Halliwell 1999;
Tabet 2001; Tabet 2002). In addition, the central nervous system
(CNS) contains high levels of unsaturated fatty acids that are
substrates for peroxidation reactions (Ogawa 1994). An important
defence mechanism in the brain involves enzymatic antioxidants
which, if mediated through the supplementation of micronutrients,
may replenish the brain with synthetic antioxidants providing
a therapeutic approach to reduce oxidative stress (Reiter 1995).
This may be a useful adjunct in modifying risk factors in the
pathogenesis of neurodegenerative disorders (Packer 1997).
Vitamins:
Vitamins have a wide range of roles in the central nervous system
and hence may a%ect the pathophysiological processes underlying
the dementias in numerous di%erent ways. Vitamin A may be
involved in the stabilisation of beta amyloid fibrils (Ono 2012).
Vitamin D is a precursor of hormones required for calcium and
phosphorus metabolism and also has a possible role in cognition
in older adults (Przybelski 2007). Vitamin E is an antioxidant which
provides protection against free radical damage (Farina 2012;
Takatsu 2009). B vitamins, particularly vitamin B12 and folic acid,
have a role in energy production and metabolism within the CNS.
B vitamins have also been implicated in the production of nucleic
acids and production and maintenance of myelin essential for
good neuronal health (Kühnast 2013; Osiezagha 2013; Pawlak 2014;
Powers 2003; The World Alzheimer Report 2014). See Appendix 1 for
more detail of possible mechanisms.
Minerals:
Minerals, similarly, have a very wide range of functions. For
example, some may be involved in neuronal gene expression and
the secretion of neurotransmitters (Ozawa 2012; Rossom 2012).
Potassium, calcium, and magnesium were reported to be protective
against cognitive decline in a cohort of Japanese participants
(Ozawa 2012). Selenium is a critical component of the enzyme
glutathione peroxidase and has been shown to protect the CNS and
immune system from oxidative damage by harmful free radicals
(Berr 2012; Mehdi 2013; Smorgon 2004). See Appendix 1 for more
detail of possible mechanisms.
Micronutrients may not be maximally e%ective if supplemented
in isolation. There are some patented formulas consisting of
complex mixtures of micronutrients which are claimed to work
synergistically. These are sometimes marketed as licensed medical
foods. These licensed medical foods are not covered in this set of
reviews.
Why it is important to do this review
The prevalence and financial implications of dementia are such
that small e%ects on cognitive decline or on the incidence of
dementia may have a large impact on healthcare costs and the
overall burden of dementia. Robust assessments are needed of
the e%ect size of interventions and of the ‘dose’ and duration of
intervention necessary to achieve an e%ect.
For individuals, fear of cognitive decline and dementia may be a
powerful motivator to seek preventive interventions. Nutritional
supplements and cognitive activities (e.g. computerised 'brain
training' games), in particular, are subject to promotion by
those with commercial interests. It is important for people to
know whether time, e%ort, and money they might invest to
prevent cognitive decline is likely to be well spent. Information
about adverse e%ects is also important. Although nutritional and
behavioural interventions are oSen perceived to be ‘low risk’,
they are not necessarily without the potential to cause harm. For
example, trials have found high doses of vitamin E to be associated
with more adverse e%ects than placebo (Bjelakovic 2012; Brigelius-
Flohe 2007; Miller 2005).
People with MCI are interested in interventions which could prevent
or delay further cognitive decline. In addition, this review will be
of interest to clinicians providing care for people with MCI and to
policy makers.
O B J E C T I V E S
To evaluate the e%ects of vitamin and mineral supplementation on
cognitive function and the incidence of dementia in people with
mild cognitive impairment.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included in the review randomised or quasi-randomised
controlled trials, published or unpublished, reported in any
language. We included studies involving both randomised and non-
randomised trial arms, but we only considered results from the
former. We included cross-over studies, but extracted and analysed
data from the first treatment period only.
Types of participants
We included the following population: people diagnosed with mild
cognitive impairment (MCI) according to internationally accepted
and validated criteria. We recorded definitions. Participants
should have been reported to be free of dementia at baseline.
Consequently, we included only trials which assessed cognitive
function or dementia status with internationally accepted and
validated instruments at baseline and follow-up.
We excluded trials of participants with severe vitamin or mineral
deficiency where the intervention given could correct these
deficiencies.
Types of interventions
We included studies comparing the e%ects of the described vitamin
and mineral supplements with control interventions that were
not expected to have specific risk-modifying e%ects. The control
arms typically involved placebo or no intervention/usual care. The
minimum treatment duration was set at 12 weeks. Experimental
interventions could be single vitamin or mineral supplements or
combination treatments with any of the supplements listed in
Appendix 1. We excluded trials of vitamins or minerals given in
combination with other unrelated compounds (e.g. amino acids,
fatty acids, or medications) unless the e%ects of the vitamins
and minerals could be isolated. For example, a trial evaluating
the e%ects of vitamin A and C versus methionine would have
been excluded, whereas a trial evaluating vitamin A and C with
methionine versus methionine only would have been included.
We included only orally-administered supplements. There were no
restrictions on dose.
Types of outcome measures
Primary outcomes
1. The incidence of all-cause dementia (assessed using
internationally accepted and validated criteria).
The main time point of interest was end of trial, defined as
the time point with the longest follow-up duration as measured
from randomisation (see also section, Data extraction and
management). Outcome data reported at other time points aSer
randomisation were extracted and presented. For this outcome, the
minimum follow-up period was 12 months.
2. Overall cognitive functioning, measured with, for example,
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-
cog); the Mini Mental State Examination (MMSE); Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS);
Cambridge Cognition Examination (CAMCOG).
Secondary outcomes
Secondary outcomes were any internationally accepted and
validated measures of:
- specific cognitive functioning subdomain: episodic memory,
- specific cognitive functioning subdomain: executive functioning,
- specific cognitive functioning subdomain: speed of processing,
- quality of life, either generic or disease-specific,
- clinical global impression,
- functional performance,
- number of participants experiencing one or more serious adverse
events (SAE),
- mortality.
- biomarkers: where studies included validated biomarkers (e.g.,
beta-amyloid or tau in cerebrospinal fluid, structural MRI or
amyloid imaging) as well as cognitive outcomes, biomarker data
were extracted.
Outcomes included in the 'Summary of findings' table
Critical e%ectiveness outcomes included in the 'Summary of
findings' table for this review were incidence of dementia, all
outcomes related to cognitive functioning, quality of life, and
mortality.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane
Dementia and Cognitive Improvement Group’s (CDCIG) specialised
register on 25 January 2018.
ALOIS is maintained by the Information Specialists for the CDCIG,
and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy elderly populations. The studies are
identified through:
1. Monthly searches of a number of major healthcare databases:
MEDLINE, Embase, CINAHL, PsycINFO and LILACS;
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan's Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials, and the Netherlands National Trials Register, plus
others);
3. Quarterly search of the Cochrane Library's Central Register of
Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources: ISI
Web of Science Core Collection; Index to Theses; Australasian
Digital Theses.
To view a list of all sources searched for ALOIS, see 'About ALOIS' on
the ALOIS website (www.medicine.ox.ac.uk/alois).
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Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia,
cognitive improvement, and cognitive enhancement trials, can
be viewed in the ‘methods used in reviews’ section within the
editorial information about the Cochrane Dementia and Cognitive
Improvement Group.
We ran additional searches in MEDLINE, Embase, PsycINFO,
CENTRAL, CINAHL, Web of Science Core Collection, LILACs,
ClinicalTrials.gov, and the WHO Portal/ICTRP to ensure that the
searches for each suite of reviews was as comprehensive and as up-
to-date as possible to identify published, unpublished, and ongoing
trials. The search strategies used for the retrieval of reports of trials
can be seen in Appendix 2.
Searching other resources
We screened reference lists of all included trials. In addition,
we screened reference lists of recent systematic reviews, health
technology assessment reports, and subject-specific guidelines
identified through www.guideline.gov. The search was restricted to
those guidelines meeting the 2013 inclusion criteria of the National
Guideline Centre (NGC), published in this year or later.
We contacted experts in the field and companies marketing
included interventions, in order to provide additional randomised
trial reports that were not identified by the search.
Data collection and analysis
We used this protocol, alongside instructions for data extraction,
quality assessment, and statistical analyses which were based on
a generic protocol generated by the editorial board of CDCIG to
guide this and another 11 reviews on modifiable risk factors (see
Acknowledgements).
Selection of studies
If multiple reports described the same trial, we included all to allow
complete extraction of the trial details.
We used crowdsourcing to screen the search results. Details of this
method have been described here (http://www.medicine.ox.ac.uk/
alois/content/modifiable-risk-factors). In brief, teams of volunteers
performed a ‘first assess’ on the search results. The volunteers were
recruited through the author team’s institutions. They screened the
results using an online tool developed for Cochrane Embase project
but tailored for this programme of work. The crowd decided,
based on a reading of title and abstract, whether the citation was
describing a randomised or quasi-randomised trial, irrespective of
the citations topic. The citations identified as possibly relevant by
the crowd were then screened by the author team.
Data extraction and management
Two review authors, working independently, extracted trial
information using a standardised and piloted extraction method,
referring also to a guidance document. Discrepancies were resolved
by discussion, or by the involvement of a third reviewer. Where
possible, we extracted (as a minimum) the following information
related to characteristics of participants, intervention, and study
design:
Participant characteristics• gender
• baseline age (range, median, mean)• education (level and years of education)• baseline cognitive function• cognitive diagnostic status• duration of cognitive symptoms, if any• ethnicity• Apo-E genotype• diabetes mellitus (yes/no)• physical activity (as defined by the trialists).• smoking (never/ever)
Intervention characteristics• nature of the intervention/generic and trade name of
intervention• description of the control condition• duration of treatment• dosage and frequency• any concomitant treatments• treatment adherence
Methodological characteristics• trial design (individual or cluster randomisation; parallel group,
factorial or cross-over design)• number of participants• outcome measures used• duration of follow-up, as measured from randomisation• duration of follow-up, as measured from end of treatment• source of financial support• publication status
If secondary outcome data were available at multiple time-points
within a given trial, we grouped them as follows: immediate (up
to 12 weeks), short-term (up to one year), medium-term (one to
two years) and longer-term results (more than two years). For
the primary outcome (all-cause dementia), we considered only
outcome data at one year of follow-up or longer. Within these time
periods, we extracted the latest available data reported by the
study. For example, if a study reported data at six months, nine
months and one year, we extracted and analysed only the one-year
data for the one-year (short-term) time point.
For dichotomous outcomes (such as incident dementia or
mortality), we extracted from each trial the number of participants
with each outcome at each time point.
For continuous outcomes, we extracted the number of participants
in whom the outcome was measured, and the mean and standard
deviation of the change from baseline for each outcome at each
time point. If change-from-baseline data were not available, we
extracted the mean value at each time point. When necessary,
means and measures of dispersion were approximated from figures
in the reports.
Whenever possible, we extracted intention-to-treat data, i.e.
analysing all participants according to the group randomisation;
if this was not available, then we extracted and reported data
from available case analyses. If neither of these types of data were
available, we considered data from 'per protocol' analyses. We
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contacted the trialists if we were unable to obtain the necessary
data from the trial report.
Assessment of risk of bias in included studies
ASer completion of a standardised training session provided
by AR, one member of the author team and one experienced
reviewer provided by the editorial team independently assessed
the risk of bias in each of the included trials using the Cochrane's
'Risk of bias' tool (Higgins 2011). We resolved disagreements by
consensus. We assessed the risk of bias potentially introduced by
suboptimal design choices with respect to sequence generation,
concealment of allocation, blinding of participants and caregivers,
blinded outcome assessment, selective outcome reporting, and
incomplete outcome data, including the type of statistical analyses
used (true intention-to-treat versus other analyses). The general
definitions that were used are reported in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment e:ect
We expressed the measure of treatment e%ect for continuous
outcomes as a mean di%erence if all included studies used the same
outcome measure and as a standardised mean di%erence (SMD),
defined as the between-group di%erence in mean values divided
by the pooled standard deviation (SD), if the same outcome was
assessed with a variety of measurement scales. We expressed the
treatment e%ect for dichotomous outcomes as a relative risk (RR).
Unit of analysis issues
We did not identify any cross-over or cluster-randomised trials for
inclusion.
Dealing with missing data
Missing data in individual trials may put the study estimates of
e%ects at a high risk of bias, and may lower the overall quality of the
evidence according to GRADE (Higgins 2011). We dealt with missing
data in our 'Risk of bias' assessments and evaluated attrition bias
in stratified analyses of the primary outcomes (Appendix 2). We
analysed the available information and did not contact authors
with a request to provide missing information; nor did we impute
missing data ourselves.
Assessment of heterogeneity
We examined heterogeneity in stratified analyses by trial,
participant, and intervention characteristics, as outlined in the
sections Data and analyses and Appendix 2.
Assessment of reporting biases
We identified too few trials to allow the use of funnel plots to
explore reporting biases or other small study e%ects.
Data synthesis
We examined participants, interventions, and outcomes in the
included trials in order to decide whether they were su%iciently
similar for data to be pooled.
Where we considered it appropriate to pool data, we
used standard inverse-variance random-e%ects meta-analysis to
combine outcome data across the trials at the end of trials
(DerSimonian 1986); and, if possible, at least one additional
time point (see Primary outcomes and Data extraction and
management for definitions of time points). We visually inspected
forest plots for the presence of heterogeneity and calculated the
variance estimate tau2 as a measure of between-trial heterogeneity
(DerSimonian 1986). We prespecifed a Tau2 of 0.04 to represent
low heterogeneity, 0.09 to represent moderate heterogeneity, and
0.16 to represent high heterogeneity between trials (Spiegelhalter
2004). We also presented the I2 statistic and the corresponding
Chi2 test (Higgins 2003). I2 describes the percentage of variation
across trials attributable to heterogeneity rather than to chance,
with values of 25%, 50%, and 75% typically being interpreted as
low, moderate, and high between-trial heterogeneity. We preferred
Tau2 over I2 in the interpretation of between-trial heterogeneity, as
the interpretation of I2 can be largely a%ected by the precision of
trials included in the meta-analysis (Rücker 2008). We did statistical
analyses in Review Manager 5 (RevMan 2014) and in STATA, release
13 (StataCorp, College Station, Texas).
Subgroup analysis and investigation of heterogeneity
We had prespecified the following trial characteristics as of interest
for exploring possible heterogeneity: concealment of allocation,
blinding of participants, blinded outcome assessment, intention-
to-treat analysis, trial size (based on power calculation for trial
primary outcome), duration of treatment (<3, 3-12, >12 months),
and length of follow-up from randomisation (<3 months, 3-12
months, >1-2 years, >2 years). We had also prespecified the
following possible clinical e%ect modifiers: age (40-65 or >65 years),
comorbidities, concomittant medications, and ethnicity (Dawson-
Hughes 2004). However, too few studies were included to allow
us to conduct subgroup analyses or explore the e%ect of these
features. Because B vitamins may work by lowering homocysteine
levels and therefore may be more e%ective in participants with high
homocysteine levels at baseline, we decided to amend the protocol
to report the e%ects of B vitamins in subgroups of participants
distinguished by level of homocysteine at baseline, where this was
reported in the included studies (see Di%erences between protocol
and review).
Sensitivity analysis
We had prespecified a sensitivity analysis for the primary
e%ectiveness outcome, including high-quality trials only. However,
too few trials were included for this to be done.
GRADE and summary of findings table
We used GRADE to describe the quality of the overall body of
evidence for each outcome in the 'Summary of findings' table
(Higgins 2011; Guyatt 2008).
Quality in GRADE is defined as the degree of confidence which can
be placed in the estimates of treatment benefits and harms. There
are four possible ratings: 'high', 'moderate', 'low' and 'very low'.
Rating evidence as 'high-quality' implies that we are confident in
our estimate of the e%ect, and further research is very unlikely to
change this. A rating of 'very-low' quality implies that we are very
uncertain about the obtained summary estimate of the e%ect.
The GRADE approach rates evidence from RCTs which do not have
serious limitations as 'high-quality'. However, several factors can
lead to the downgrading of the evidence to 'moderate', 'low' or 'very
low'. The degree of downgrading is determined by the seriousness
of these factors: study limitations (risk of bias); inconsistency;
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indirectness of evidence; imprecision; and publication bias (Higgins
2011; Guyatt 2008; Chandra 2001).
R E S U L T S
Description of studies
Results of the search
We conducted searches in December 2014, July 2015, March 2016,
August 2016, March 2017, and January 2018. In total, we retrieved
7,257 records from the six searches. ASer de-duplication, 5211
records remained. A Crowd and the CDCIG information specialist
assessed these at title and abstract level. In total, 725 results
remained aSer this assessment. The review team then screened
these records. Of these, we assessed 110 full-text articles describing
67 trials for eligibility and included eight trials in the review
(one aSer the authors provided subgroup data). Three trials, one
described in three papers, were placed in the section 'Awaiting
classification'; we sought information from the authors of these
trials but received none. We identified one ongoing study of vitamin
D supplementation which was due to be completed in July 2018.
This process is depicted in Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
We identified eight studies eligible for inclusion in this review. For
full details see Characteristics of included studies.
We grouped the studies into four comparisons. Five studies
compared B vitamins to placebo (de Jager 2012, Eussen 2006, Fan
2017, Ting 2017, van U%elen 2008). One study compared vitamin E
to placebo (Petersen 2005), one compared vitamin E + vitamin C to
placebo (Naeini 2014), and one compared chromium picolinate to
placebo (Krikorian 2010).
Appendix 3 shows the supplement doses used in the studies in
relation to the mean daily intake from food and the recommended
daily intake for adults in the UK.
Comparison 1: B vitamins versus placebo - description of studies
Five studies with 879 randomised participants contributed data to
this comparison.
Setting
The studies were conducted in the UK, the Netherlands (2 studies),
China and Singapore. Eussen 2006 included participants living in
the community or in a care home; participants in all other studies
were resident in the community.
Participants
All studies specifically excluded participants with dementia.
de Jager 2012, Fan 2017 and van U%elen 2008 used broadly
similar criteria for MCI, which included a memory complaint and
scores within a specified range on scales of cognition and daily
functioning. Participants in Eussen 2006 had a Clinical Dementia
Rating (CDR) global score of 0 or 0.5; for this review we, used
data from the participants with a CDR score of 0.5. All participants
in Ting 2017 had recent lacunar stroke and cognitive impairment
- no dementia (CIND); the cognitive impairment was defined as
scoring at least 1.5 SDs below expected in at least one domain of a
neuropsychological test battery.
All participants in Eussen 2006 met the authors' criteria for mild B12
deficiency.
Four studies had age-based inclusion criteria: de Jager 2012 and
Eussen 2006 only included participants aged 70 or older, Fan 2017
only included participants aged 60 to 75 years, and van U%elen 2008
included participants aged 70 to 80 years. Across all studies, the
mean age of participants ranged from approximately 66 years (Fan
2017) to approximately 80 years (Eussen 2006).
Interventions
All studies were placebo-controlled. The experimental
interventions varied in composition and dose.
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• Participants in de Jager 2012 received 0.5 mg B12 + 0.8 mg folic
acid + 20 mg B6 once daily for two years.• Eussen 2006 was a three-arm study. For this review, we
combined the groups receiving 1 mg B12 and 1 mg B12 + 0.4
mg folic acid into a single experimental intervention group.
Treatment was once daily for 24 weeks.• Participants in Fan 2017 received 0.4 mg folic acid once daily for
six months.• Participants in Ting 2017 received 0.5 mg B12 + 2 mg folic acid +
25 mg B6 once daily for one to five years.• Participants in van U%elen 2008 received 0.4 mg vitamin B12 + 5
mg folic acid + 50 mg vitamin B6 once daily for a year. This study
also investigated the e%ect of aerobic exercise in a 2 x 2 factorial
design. For the purposes of this review, we combined data for
all participants receiving vitamin B supplementation or placebo
(i.e. with or without aerobic exercise) into single experimental
and control groups.
Outcomes
None of the studies reported on our primary outcome of incidence
of all-cause dementia (although diagnosis of dementia by DSM-
IV was listed as a secondary outcome in the protocol for de Jager
2012).
Four of the five studies measured overall cognitive function with the
MMSE (de Jager 2012, Fan 2017, Ting 2017, van U%elen 2008).
We were able to extract data on episodic memory from three
studies, which assessed delayed recall on the Hopkins Verbal
Learning Test (de Jager 2012), word learning (Eussen 2006) and
the Auditory Verbal Learning Test (van U%elen 2008). We extracted
data on executive function from four studies, which used CLOX (de
Jager 2012), the Stroop test (Eussen 2006; van U%elen 2008) and the
Frontal Assessment Battery (Ting 2017). We extracted data on speed
of processing from three studies, which used Trail-making Test A
(Eussen 2006), digit cancellation (Ting 2017), and the Digit-Symbol
Substitution Test (van U%elen 2008).
Only van U%elen 2008 reported on quality of life, using the
dementia-specific D-QOL scale.
de Jager 2012 reported overall clinical impression using global CDR
scores.
Fan 2017 reported functional performance on a 14-item Chinese
ADL scale.
de Jager 2012 reported e%icacy results separately for participants
with high or low total homocysteine (tHCy) (based on the median
values at baseline). However, it was possible to calculate results
for the whole experimental intervention and control groups from
the reported means and standard deviations. van U%elen 2008
reported results for men and women separately in each group, but
some of the outcomes were reported in enough detail to allow us
to combine the data for men and women.
Data on adverse events were reported by de Jager 2012 and van
U%elen 2008.
Comparison 2: Vitamin E versus placebo - description of study
One study with 769 participants investigated this comparison
(Petersen 2005). The study also had a donepezil arm. The primary
outcome of the study was time to development of possible or
probable Alzheimer's disease.
Setting
The study took place at 69 Alzheimer's Disease Cooperative Study
(ADCS) sites in the US and Canada.
Participants
Participants were aged 55 to 90 years and had amnestic
MCI of a degenerative nature (insidious onset and gradual
progression). Specific cognition-related inclusion criteria were
impaired memory, a logical memory delayed-recall score
approximately 1.5 to 2 SD below an education-adjusted norm and
a score of 24 to 30 on the MMSE, as well as a CDR global score of 0.5.
Intervention
The experimental group of interest to this review received 2000
IU vitamin E (1000 IU twice daily), placebo donepezil, and a
multivitamin (containing 15 IU of vitamin E) for three years. The
comparator group received placebo vitamin E, placebo donepezil
and the same multivitamin. Any participant who met clinical
criteria for Alzheimer's disease at any time in the study was o%ered
open-label donepezil until study completion.
Outcomes
The study assessed progression to possible or probable Alzheimer's
disease. Overall cognitive function was assessed with the MMSE
and with a composite score derived from a battery of individual
neuropsychological tests. Composite scores of interest to this
review were also derived for the domains of memory and executive
function (and additional composites for language and visuospatial
function). Clinical global impression was assessed using the Global
Deterioration Scale (GDS) and the CDR. Functional performance
was assessed using the ADCS Mild Cognitive Impairment ADL Scale.
Data on individual adverse events were reported by treatment
group if they occurred in at least 5% of subjects in the donepezil or
vitamin E group and at least two times in the placebo group during
the double-blind phase. The number of deaths in each treatment
group was also reported.
Comparison 3: Vitamin E + vitamin C versus placebo - description
of study
One study investigated this comparison (Naeini 2014). It reported
data on the 256 participants who completed the study (out of 296
who were randomised).
Setting
The study took place at a single centre in Iran with participants
recruited from community clubs for retired people.
Participants
Dementia was listed as an exclusion criterion, but there was no
information on how this was applied. Participants were defined
as having MCI and identified as eligible for inclusion on the basis
of a score of 21 to 26 on the validated Iranian version of the
MMSE. We considered this not to be an adequate definition of MCI.
However, we decided to include the study, downgrading the result
for indirectness in relation to our review question.
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Intervention
The experimental intervention was 300 mg vitamin E (DL-alpha-
tocopherol) + 400 mg vitamin C once daily for one year. The
comparator was placebo.
Outcome
The only outcome of interest to this review was overall cognitive
functioning assessed with the MMSE.
Comparison 4: Chromium picolinate versus placebo - description
of study
One small study with 26 participants contributed data to this
comparison (Krikorian 2010).
Setting
This single centre study recruited participants via community
advertisement.
Participants
Participants had a global rating of 0.5 on the CDR.
Intervention
The experimental intervention was chromium picolinate
containing 1000 mcg elemental chromium once daily for 12 weeks.
The comparator was placebo.
Outcome
The only outcome of interest to this review was episodic memory
assessed with the California Verbal Learning Test (CVLT).
Excluded studies
The Characteristics of excluded studies table shows the reasons
for exclusion of 55 studies which were assessed in full text. The
most common reasons for exclusion were the wrong population
(participants did not have MCI) or the wrong intervention (included
additional components or was given for less than 12 weeks).
Three studies are awaiting classification. In all three cases, we have
been unable to obtain additional information from the authors
at the time of writing. No results were available from one study.
Results from the other two trials have been published, but we
considered that essential information on various details of the
methods, sample sizes, or results was missing.
We identified one ongoing trial of vitamin D supplementation
which, according to the trial register, was due to be completed in
July 2018.
Risk of bias in included studies
We describe the risk of bias of the included studies in the table,
Characteristics of included studies. Our 'Risk of bias' judgments are
also depicted in the 'Risk of bias' summary and 'Risk of bias' graph
(Figure 2 and Figure 3).
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
Three studies (de Jager 2012, Petersen 2005, Ting 2017) provided
enough information to judge the risk of selection bias to be low.
The remaining five studies provided insu%icient information on
randomisation methods so we judged them to be at unclear risk of
selection bias.
Blinding
Fan 2017 was an open-label study which we judged to have a high
risk of performance bias and an unclear risk of detection bias. There
was also a lack of information about blinding from Krikorian 2010
and Naeini 2014. The other studies were at low risk of bias in this
domain.
Incomplete outcome data
The longer studies - Petersen 2005 and Ting 2017 - lost high
numbers of participants to follow-up and we considered them to
be at high risk of attrition bias by the end of the study. We judged
the risk of attrition bias in Naeini 2014 to be unclear due to a lack
of information on the group allocation of those who dropped out.
The risk was also unclear in Krikorian 2010, where there was no
information about whether or not there were any missing data. The
remaining studies were at low risk of bias in this domain.
Selective reporting
We judged there to be a high risk of reporting bias in two studies.
de Jager 2012 mentioned a number of outcomes in the protocol,
including some relevant to this review, which were not reported.
Petersen 2005 reported composite z-scores rather than individual
test results and did not report the number of participants in each
analysis. Ting 2017 may have selected only some cognitive results
from a larger neuropsychological test battery; we judged its risk of
reporting bias to be unclear. We judged the risk in the other studies
to be low, although for some studies there was no protocol and this
judgement was based on the outcomes mentioned in the Methods
sections of the papers being fully reported.
Other potential sources of bias
We found no other obvious sources of bias and rated this risk as low
for all studies.
E:ects of interventions
See: Summary of findings for the main comparison B vitamins
compared to placebo for MCI; Summary of findings 2 Vitamin E
compared to placebo for MCI; Summary of findings 3 Vitamin E +
vitamin C compared to placebo for MCI
Comparison 1: B vitamins (folic acid, B12, B6) versus placebo
Five studies contributed data to this comparison (de Jager 2012;
Eussen 2006; Fan 2017; Ting 2017; van U%elen 2008).
Ting 2017 di%ered significantly from the other studies in recruiting
only participants who had a recent history of lacunar stroke
and in following them up for up to five years. In our primary
analyses, in order to maximise comparability with the other studies,
we included data from the one-year outcome point from Ting
2017, but we considered the population as a potential source of
heterogeneity. We also reported the results of this study at later
time points, although these were all associated with substantial
loss of participants from follow-up.
de Jager 2012 reported the data for participants with higher
(above median) baseline total homocysteine (tHcy) and lower
baseline total homocysteine levels separately. For the primary
analyses, we combined these groups. However, we also reported
and commented on their subgroup data.
van U%elen 2008 reported results separately for men and women;
we have combined these data where we incorporated them in
meta-analyses.
Primary outcomes
Incidence of all-cause dementia
No study reported the incidence of all-cause dementia.
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Overall cognitive functioning
Four studies used the MMSE to assess overall cognitive functioning
(de Jager 2012; Fan 2017; Ting 2017; van U%elen 2008). It is
unknown what would constitute an important di%erence in MMSE
score in this population. It is unlikely that MMSE is sensitive to
small changes in cognition in people with MCI. We pooled data from
three studies which reported MMSE in the form of mean score with
standard deviation in each treatment group.
van U%elen 2008 presented MMSE results as medians with
interquartile ranges (IQR) for men and women separately. ASer 12
months of treatment, the median (IQR) MMSE score among men
was 28 (27 to 30) in the vitamin group and 29 (28 to 29) in the
placebo group. For women, the median (IQR) MMSE score was
identical in both vitamin and placebo groups: 29 (27 to 30).
The pooled analysis of MMSE scores from the other three studies
aSer six to 24 months was inconclusive due to imprecision;
although the result slightly favoured B vitamins, we could not
exclude the possibility of there being little or no e%ect (MD 0.44,
95%CI -0.23 to 1.12, 3 studies, 488 participants; Analysis 1.1, Figure
4). There was high heterogeneity in this analysis (I2 = 87%). This
appeared to be due to a beneficial e%ect of B vitamins on MMSE
score in Fan 2017, which was the only open-label (unblinded)
study. We considered the evidence behind this result to be very
low-quality because of the imprecision, study limitations, and
inconsistency.
 
Figure 4.   Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.1 Overall cognitive function (MMSE).
 
de Jager 2012 reported the data separately for participants with
higher and lower baseline total homocysteine (tHcy). The results
in these subgroups were also imprecise: higher baseline tHcy (MD
0.70, 95% CI -0.16 to 1.56; participants = 111); lower baseline tHcy
(MD -0.30, 95% CI -1.10 to 0.50; participants = 112).
Ting 2017 did not find any significant e%ect of B vitamins on MMSE
at any later time point (up to five years).
Secondary outcomes
Specific cognitive functioning subdomain: episodic memory
We pooled data on episodic memory from three studies (de Jager
2012; Eussen 2006; van U%elen 2008). All used tests which involved
delayed recall of word lists. There was probably little or no e%ect of
six to 24 months of B vitamin supplementation on episodic memory
(SMD 0.09, 95% CI -0.10 to 0.29; 3 studies, 397 participants; Analysis
1.2; Figure 5). Heterogeneity was low (I2 = 0%). We considered this
to be moderate-quality evidence, downgraded due to imprecision.
 
Figure 5.   Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.2 Episodic memory.
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In de Jager 2012, there was better episodic memory aSer 24 months
in the group treated with vitamin B than in the group treated
with placebo among participants with higher baseline tHCy (MD
1.30, 95% CI 0.02 to 2.58; participants = 111), but episodic memory
did not di%er significantly between intervention groups among
participants with lower baseline tHcy (MD -0.30, 95% CI -1.58 to
0.98; participants = 112). The authors had analysed this outcome by
logistic regression at five time points, starting from the 3rd month
of the study, and estimated that aSer two years of the vitamin
B intervention, participants taking vitamin B had a 69% higher
likelihood of correct word-recall than those taking placebo (OR
1.69, P = 0.001) (de Jager 2012).
Specific cognitive functioning subdomain: executive functioning
Four studies assessed executive functioning using three di%erent
measures (de Jager 2012; Eussen 2006; Ting 2017; van U%elen
2008). We used CLOX-1 data from the CLOX test and 'task 3' from
the Stroop Colour-Word Test. Ting 2017 reported only change-from-
baseline data, so we were unable to pool these with data from
the other studies. There was probably little or no e%ect of six to
24 months of B vitamin supplementation on executive functioning
(SMD 0.03, 95% CI -0.23 to 0.29; 3 studies, 392 participants;
Analysis 1.3; Figure 6). Heterogeneity was modest (I2 = 30%). We
considered this to be moderate-quality evidence, downgraded
due to imprecision. Ting 2017 reported no significant di%erence
between B vitamin and placebo groups on change from baseline in
the Frontal Assessment Battery at any time point from one to five
years.
 
Figure 6.   Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.3 Executive function.
 
From de Jager 2012, there was no evidence of a di%erence in CLOX-1
score between intervention groups among participants with either
higher baseline tHcy (MD 0.30, 95% CI -0.50 to 1.10; participants
= 111) or lower baseline tHCy (MD 0.50, 95% CI -0.13 to 1.13,
participants = 112).
Ting 2017 did not find any significant e%ect of B vitamins on
executive functioning at any later time point (up to five years).
Specific cognitive functioning subdomain: speed of processing
Three studies assessed speed of processing using three di%erent
measures (Eussen 2006; Ting 2017; van U%elen 2008). Again,
we were unable to include data from Ting 2017 in the meta-
analysis because only change-from-baseline data were available.
There was probably little or no e%ect of six to 24 months of B
vitamin supplementation on speed of processing (SMD 0.04, 95%
CI -0.26 to 0.34; 2 studies, 173 participants; Analysis 1.4; Figure
7). Heterogeneity was low (I2 = 0%). We considered this to be
moderate-quality evidence, downgraded due to imprecision. Ting
2017 reported no significant di%erence in change-from-baseline of
speed of processing (digit cancellation) between B vitamin and
placebo groups at any time point from one to five years.
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Figure 7.   Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.4 Speed of processing.
 
Ting 2017 did not find any significant e%ect of B vitamins on speed
of processing at any later time point (up to five years).
Quality of life, either generic or disease-specific
One study (van U%elen 2008) reported dementia-specific quality of
life using D-QOL.There was no evidence of any e%ect of B vitamins
aSer one year (MD 0, 95% CI -0.1 to 0.1; 1 study, 138 participants;
Analysis 1.5). We considered this to be moderate-quality evidence,
downgraded due to imprecision.
Clinical global impression
de Jager 2012 assessed overall clinical state using CDR. The authors
reported that "(i)n the whole intention-to-treat cohort, there was
no significant e%ect of B vitamins on CDR (P = 0.23)", nor was there a
significant interaction with baseline tHcy split by median. However,
when they stratified tHcy by quartiles, they noted a significant
benefit of B vitamins on CDR in the quartile with the highest tHcy
at baseline (P = 0.039, Fisher's exact test). In this subgroup, they
calculated that "the odds of having CDR=0 at follow-up is five times
greater in the active-treatment group compared with placebo (P
= 0.02)." It was not clear whether or not this was a prespecified
analysis.
Functional performance
One study (Fan 2017) assessed functional performance using a 14-
item ADL scale (range of possible scores 14 to 56, with a lower score
representing a better outcome). There may be a small beneficial
e%ect of B vitamins on functional performance aSer six months (MD
-0.78, 95% CI -1.35 to -0.21; 1 study, 75 participants; Analysis 1.6). We
considered this to be very low-quality evidence, downgraded due
to imprecision and very serious concern about study limitations.
Number of participants experiencing one or more serious adverse
events (SAE)
Two papers reported adverse events. van U%elen 2008 reported
minor adverse events in 3/179 randomised participants (2 in B
vitamins group, 1 in placebo group). de Jager 2012 reported 242
adverse events in total in the B vitamins group (n = 133) and 271 in
the placebo group (n = 133) over two years.
Mortality
de Jager 2012 reported two deaths in the B vitamins group (2/133)
but none in the placebo group (0/133). No deaths were reported by
the other studies.
Biomarkers
de Jager 2012 reported the rate of brain atrophy measured by MRI.
Out of 133 participants who started treatment in each group, 85 in
the vitamin and 83 in the placebo group had serial MRI scans which
were technically suitable for analysis. ASer adjustment for age, the
rate of brain atrophy per year was reported to be 29.6% lower in
the active treatment group (0.76%, 95% CI 0.63 to 0.90) than in the
placebo group (1.08%, 95% CI 0.94 to 1.22) (P = 0.001).
Comparison 2: Vitamin E versus placebo
One study with 516 participants contributed data for this
comparison (Petersen 2005).
Sample sizes for change scores were not reported for some
outcomes, making it impossible to re-analyse the data without
imputation of sample sizes. It was di%icult to tell how the
study had treated the missing data arising from participants who
discontinued the study during the double-blind phase (reported
as 72 in the vitamin E group and 66 from the placebo group), and
participants who had developed Alzheimer’s Disease by 36 months
and had therefore been transferred to an open-label phase for
treatment with donepezil (76 participants in the vitamin E group
and 73 in the placebo group).
A z-score was calculated for cognitive domain scores. Positive
numbers on this score indicated better outcomes.
Primary outcomes
Incidence of all-cause dementia
The study did not report the incidence of all-cause dementia, but
did report the incidence of Alzheimer's dementia. By 12 months,
33 participants in the vitamin E group and 38 in the placebo group
had progressed to Alzheimer's dementia. By 36 months, these
numbers were 76 and 73 respectively. There was no significant
di%erence between vitamin E and placebo groups in the probability
of progression from MCI to Alzheimer's dementia over 36 months
based on Cox analysis (HR 1.02; 95% CI 0.74 to 1.41; n = 516; 1 study)
(Petersen 2005). There was also no significant di%erence between
groups at any of the six-monthly time points between baseline
and 36 months (prespecified analyses). We considered this to be
moderate-quality evidence, downgraded due to imprecision.
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Overall cognitive functioning
This was measured using MMSE and ADAS-Cog at a six-monthly
interval from baseline for three years. At 36 months, the change
from baseline in MMSE score (range 0 to 30, a higher score was
better) was -2.20 ± 3.64 in the vitamin E group and -2.75 ± 4.04
in the placebo group. This was reported not to be statistically
significant. We were not able to calculate the mean di%erences
since sample sizes were not reported. There was also reported to be
no significant di%erence in the change from baseline for ADAS Cog
(modified) score (range 0 to 85, a higher was worse); this was 3.98
± 7.56 in the vitamin E group and 3.72 ± 8.54 in the placebo group.
We considered this to be low-quality evidence, downgraded due to
risk of bias and imprecision (single study, estimated sample size).
Secondary outcomes
We considered the evidence on all of the secondary outcomes
reported here to be low-quality, downgraded due to risk of bias and
imprecision (single study, estimated sample size in each analysis).
Specific cognitive functioning subdomain: episodic memory
The study reported the change from baseline in a standardised z-
score for a memory domain, incorporating ADAS-cog immediate
and delayed word-recall scores and the New York University
immediate and delayed paragraph-recall scores. Positive numbers
indicated improvement. At 36 months, the change from baseline
was -0.31 ± 0.59 in the vitamin E group and -0.28 ± 0.62 in the
placebo group. This was reported not to be statistically significant.
Sample size was not reported.
Specific cognitive functioning subdomain: executive functioning
The study reported the change from baseline in a standardised
z-score for an executive function domain, incorporating the
Digits-Backward test, Symbol Digit Modalities test, and Number-
Cancellation test. Positive numbers indicated improvement. At 36
months, the change from baseline was -0.19 ± 0.48 in the vitamin E
group and -0.19 ± 0.53 in the placebo group. This was reported not
to be statistically significant. Sample size was not reported.
Specific cognitive functioning subdomain: speed of processing
Not reported in the study.
Quality of life, either generic or disease-specific
Not reported in the study.
Clinical global impression
The study reported the change in Global Deterioration Scale (range
0 to 7, higher was worse) from baseline to 36 months (0.64 ± 0.96 in
the vitamin E group, 0.56 ± 0.99 in the placebo group). The number
of participants in the analysis was not reported. This di%erence was
described as not statistically significant in the study report.
Functional performance
This was measured with the Activities of Daily Living Scale, which
can range from 0 to 53, with higher scores indicating better function.
The change from baseline at 36 months was -5.63 ± 8.75 in
the vitamin E group and -6.39 ± 8.99 in the placebo group. The
sample sizes used to calculate these values were not reported. The
di%erence was described as not statistically significant.
Number of participants experiencing one or more serious adverse
events (SAE)
This was not reported in the study. There was no statistically
significant di%erence between vitamin E and placebo groups in the
rate of ten individual adverse events which were reported because
they occurred in at least 5% of participants receiving donepezil or
vitamin E and at least twice among participants receiving placebo.
Mortality
Five subjects died in each of the vitamin E (n = 257) and placebo (n
= 259) groups during the double-blind phase.
Other validated biomarkers
Not reported in the review.
Comparison 3: Vitamin E and C versus placebo
Only one study Naeini 2014 contributed to this comparison.
Primary outcomes
Incidence of all-cause dementia
Not assessed.
Overall cognitive functioning
This was measured using the Iranian version of the MMSE (validated
for the local population, range 0 to 30) aSer one year of treatment.
The mean and standard error of the mean at six and 12 months were
reported. The di%erence between the groups was described as not
statistically significant at either time point.
We assumed that all participants described as completing the study
were analysed and estimated the mean di%erence at the end of
the study. This indicated that there may be no little or no e%ect
of supplementation with vitamins E and C (MD 0.23, 95% CI -0.25
to 0.71; 1 study, 256 participants; Analysis 3.1).We considered this
to be very low-quality evidence, downgraded due to indirectness
(inadequate definition of MCI), risk of bias, and imprecision (result
from a single study).
Secondary outcomes
Mortality
There was one reported death, but the treatment allocation of this
person was not reported.
None of our other secondary outcomes were reported.
Comparison 4: Chromium picolinate versus placebo
Only one study Krikorian 2010 contributed data to this comparison.
This study was very small (n = 26). There were 15 participants in the
intervention arm and 11 in the placebo arm.
Primary outcomes
The incidence of all-cause dementia
Not assessed.
Overall cognitive functioning
Not assessed.
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Secondary outcomes
Specific cognitive functioning subdomain: episodic memory
This was measured using the Californian Verbal Learning test (test
for episodic verbal learning and memory) at 12 weeks. Group
di%erences were not significant for performances on the CVLT
learning trials (46.8 versus 45.8; P = 0.72), short-delay recall (9.4
versus 8.4; P = 0.30), long-delay recall (9.3 versus 9.5; P = 0.78), or
recognition memory (14.4 versus 14.2; P = 0.77). We considered this
to be very low-quality evidence due to serious concern about study
limitations and very serious concern about imprecision.
None of our other secondary outcomes were reported.
D I S C U S S I O N
Summary of main results
This review included eight RCTs which investigated the e%ect of
vitamin or mineral supplements on the incidence of dementia or on
cognitive function in participants with mild cognitive impairment
at baseline. Five studies with 879 randomised participants
investigated the e%ect of B vitamins; in four of these studies the
intervention was a mixture of vitamins B12, B6 and folic acid and
in one study it was folic acid only. The other supplements included
were vitamin E (one study, 769 participants), vitamins E and C (one
study, 256 participants) and chromium picolinate (one study, 26
participants).
None of the included studies assessed the incidence of all-cause
dementia, one of our primary outcomes. One study found that
there was probably no e%ect of vitamin E on the probability of
progression from MCI to dementia due to Alzheimer's disease over
three years.
All of the studies reported on one or more measures of cognitive
function.
For B vitamins, we found very low-quality evidence on overall
cognitive function. There was probably little or no e%ect on any
of our specific cognitive subdomains of interest (episodic memory,
executive functioning, and speed of processing). Only one study
reported on each of global clinical impression and quality of life,
and there was no evidence of any e%ect. There was only very
low-quality evidence on functional performance from one small,
open-label study. The very few data available on adverse events
or mortality did not suggest any di%erence between groups. The
only study reporting biomarker data found a reduction in the
rate of brain atrophy over two years in the B vitamin group. We
added to our protocol the reporting of subgroup data by baseline
homocysteine (tHcy) level. The one study that reported such data
found that there may be a significant benefit of B vitamins on
episodic memory - but not overall cognitive function or executive
function - of participants with tHcy above the median at baseline.
The study of vitamin E did not provide the data we needed
to conduct analyses. The authors reported no significant e%ect
of vitamin E supplementation on overall cognitive functioning,
episodic memory, executive functioning, clinical global impression,
functional performance, incidence of adverse events, or mortality.
The quality of evidence on vitamins E and C in combination (e%ect
on overall cognitive function) and on chromium picolinate (e%ect
on episodic memory) was very low so we had very little confidence
in the results.
Overall completeness and applicability of evidence
The five trials all included community-dwelling participants aged
over 55 with mild cognitive impairment. In one of the studies of B
vitamins, participants all had mild B12 deficiency at baseline at a
level which is common in older people, but otherwise participants
were not selected on the basis of nutritional status. Not all studies
assessed nutritional status at baseline, but participants in all other
studies had, or could be expected to have had, normal dietary
intake for their population of origin and a low risk of specific
vitamin or mineral deficiencies. The results of this review do not
apply to people with significant nutritional deficiencies. In one
study, participants had vascular cognitive impairment aSer a recent
lacunar stroke; in the other studies, there was no selection for
cause of cognitive impairment. Overall, the participants seemed
to be quite well representative of people with MCI seen in clinical
practice. The range of vitamin and mineral supplements tested
was limited. Only B vitamins were investigated in more than one
study and these studies all used di%erent dose combinations so
that it was not possible to isolate e%ects of individual B vitamins
or to assess dose-response relationships. The dose of folic acid
used in some studies was similar to the maximum dietary intake
in the UK population; doses of other vitamins were at least ten
times more than the reference nutrient intake (see Appendix 3).
All trials assessed di%erent primary and secondary outcomes. Only
one trial assessed progression to dementia due to Alzheimer's
disease and none assessed progression to all-cause dementia.
Overall cognitive function was assessed mainly with the MMSE
which has limited sensitivity to detect small changes in cognition in
a population with MCI. There were few data on quality of life, global
impression, functional performance, or adverse events. Only one
study reported a biomarker outcome which has been widely used
in MCI populations, namely, the rate of atrophy on structural MRI.
Quality of the evidence
There was some moderate-quality evidence relating to the e%ect
of B vitamins on specific cognitive domains and quality of life, and
the e%ect of vitamin E on incidence of Alzheimer's dementia. The
remaining evidence was of low- or very low-quality. Some of the
more serious concerns about risk of bias related to performance
bias in one open-label study, attrition bias in two studies and
selective outcome reporting in two studies. For the comparisons
of the vitamin E and C combination and chromium picolinate with
placebo, the only evidence was of very low-quality because of study
limitations and very small sample sizes. The evidence concerning a
possible di%erential e%ect on episodic memory in participants with
higher or lower baseline homocysteine levels came from subgroups
in a single study and must be regarded as preliminary.
Potential biases in the review process
We considered search biases to be unlikely. We used a standardised
search strategy to identify articles, including unpublished studies.
These search methods included a single-concept search across
multiple sources along with a search of the Cochrane trial register.
This sensitive search approach may have identified studies that
would have potentially been overlooked using less rigorous search
methods. However, we found too few studies to conduct any formal
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tests to assess the likelihood of publication bias and this remains
possible.
We selected only three specific cognitive subdomains as secondary
outcomes. It is possible that e%ects on other specific cognitive
subdomains could have been missed.
Where cognition is measured using several di%erent instruments,
it can be di%icult to categorise instruments into specific cognitive
subdomains and to make data pooling decisions. We tried to avoid
bias by using a prespecified, hierarchical list of the most commonly
used instruments, but it is possible that di%erent categorisations
could have led to di%erent results.
Agreements and disagreements with other studies or
reviews
We are not aware of other reviews of similar scope. The
Collaboration of B-vitamin Treatment Trialists have conducted a
meta-analysis of data on more than 22,000 older participants who
were not selected for specific cognitive diagnoses (Clarke 2014).
This review found no e%ect of B vitamins on overall or domain-
specific cognitive function despite lowering serum homocysteine
levels by > 25%. Although not directly relevant to a population
with mild cognitive impairment, this result does not support the
hypotheses that B vitamin supplementation or homocysteine-
lowering are e%ective means to prevent cognitive decline.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Currently, there is no evidence that any vitamin or mineral
supplement is useful for preventing progression from MCI to
dementia or for treating the symptoms of MCI.
Implications for research
Research on vitamin and mineral supplements for the treatment
of mild cognitive impairment should be driven by strong
hypotheses based on preclinical research. Studies should
investigate mechanisms by measuring putative mediating factors.
Ultimately, longer and larger studies will be needed to investigate
outcomes which are important to patients, including improved
functioning and quality of life, but at the current stage of research,
shorter term studies with surrogate outcomes (biomarkers or
cognitive test scores) remain suitable for hypothesis testing.
Outcomes should be measured across several cognitive domains
using instruments which are known to be sensitive to small
changes in the presence of mild impairments. Trials should include
evaluation of baseline nutritional status and assess how this
interacts with treatment. Other possible moderating factors, based
on the hypotheses being tested, should also be measured.
Although there was no evidence of overall benefit from the studies
included in this review, one study of B vitamins reported a slowing
of brain atrophy in the whole study population and an attempt
to replicate this result is needed. The same study reported that
there may be a beneficial e%ect of B vitamins on episodic memory
in the subgroup with higher homocysteine levels at baseline.
However, the result of a very large individual patient meta-analysis
which found no e%ect of homocysteine-lowering with B vitamins
on cognitive ageing in 22,000 older participants without specific
cognitive diagnoses at baseline makes this result less promising to
pursue.
A C K N O W L E D G E M E N T S
The protocol was largely based on a general template constructed
for the development of a larger series of protocols and reviews
covered by a National Institute for Health Research (NIHR
Systematic Reviews Programme Grant). The common protocol
covered four types of intervention, for which some evidence exists
that these may modify the risk of developing cognitive impairments
or dementia. These include vitamin and mineral supplements,
exercise, cognition, and dietary interventions. The general protocol
was inspired by a generic protocol approved by the Cochrane
Musculoskeletal Group for another series of reviews (Da Costa 2012;
Da Costa 2014; Reichenbach 2010; Rutjes 2009a; Rutjes 2009b;
Rutjes 2010).
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Characteristics of included studies [ordered by study ID]
 
Methods 2-arm, placebo-controlled, parallel group, randomised clinical trial, intervention for 2 years (trial short
name = VITACOG)
Participants Location: Oxford, United Kingdom. Single centre
Setting of recruitment and treatment: University of Oxford
Sample size:
• Number randomised: 138 in intervention, 133 in comparison• Number completed: 110 in intervention, 113 in comparison
Participant baseline characteristics:
• Age in years (mean ± SD) : vitamin B: 76.8 ± 5.1, placebo: 76.7 ± 4.8• Female sex
: vitamin B: 70 (63.6%), placebo: 73 (64.6%)
Inclusion criteria:
• Age >= 70 years• Study partner available as informant• MCI. No distinction between amnestic and non-amnestic MCI. Screened with TICSm (≥ 17 and ≤ 29) and
a category fluency test. Also MMSE ≥ 24/30, a subjective memory complaint with corroboration from
a study partner using questions from the Cambridge Examination for Mental Disorders of the Elderly
(CAMDEX) and normal activities of daily living using five questions from the Cambridge Behavioural
Inventory.
Exclusion criteria:
• A diagnosis of dementia or being treated with anti-dementia drugs• Active cancer• Major stroke within past 3 months• Treatment with methotrexate• Anti-cancer or anti-epileptic drugs• Taking folic acid > 300 mg/d, B6 >3 mg/d or vitamin B12 > 1.5 mg/d by mouth or any dose by injection
Interventions Intervention:
The B-vitamin group received TrioBe PlusW containing 0.8 mg folic acid, 0.5 mg vitamin B12 and 20 mg
vitamin B6 once daily.
Comparator:
de Jager 2012 
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Vitamin-free tablets of similar appearance.
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: MMSE, (also measured: TICSm)
Specific cognitive functioning subdomain: episodic memory: HVLT-R (Hopkins Verbal Learning Test -
Revised with delayed recall)
Specific cognitive functioning subdomain: executive functioning: CLOX, (also measured: category flu-
ency)
Clinical global impression: global CDR
Functional performance: IQCODE
Total adverse events
Mortality
Biomarker: rate of brain atrophy on volumetric MRI
Source of Funding Charles Wolfson Charitable Trust, Medical Research Council, Alzheimer’s Research Trust, Henry Smith
Charity, Thames Valley Dementias and Neurodegenerative Diseases Research Network of the UK Na-
tional Institute for Health Research, John Coates Charitable Trust, and the Sidney and Elizabeth Corob
Charitable Trust.
Recip AB donated vitamins, Axis-Shield provided assay equipment for homocysteine
Declaration of Interest "AD Smith is named as an inventor on three patents held by the University of Oxford on the use of folic
acid to treat AD or MCI (US6008221; US6127370; PCT/GB2010/051557); under the University’s rules, he
could benefit financially if the patent is exploited. Drs Refsum and Smith report having in the past re-
ceived speaking honoraria from Recip AB, the company that donated the vitamin tablets, and from Ax-
is-Shield, who make the equipment used to assay homocysteine."
Notes VITACOG study, ISRCTN 94410159, Eudract Number: 2004-001527-38
ISRCTN trial register entry refers to:
Primary outcome measures:
1. Rate of shrinkage of whole brain and/or brain regions assessed by volumetric MRI
2. Changes in performance on a variety of cognitive tests
Secondary outcome measures:
1. Trial recruitment procedures
2. Conversion to dementia
Protocol refers to:
Primary efficacy endpoints:
Clinical: rate of shrinkage of brain assessed by volumetric MRI, change in memory test score.
Secondary efficacy endpoints:
Diagnosis of dementia by DSM-IV, IQCODE, change in any of the cognitive test scores. Cognitive tests
further defined as MMSE, HVLT, paired associates learning (PAL), CLOX, Trailmaking, category fluency,
SDMT, Map search/attention task, TICSm.
Safety and other endpoints:
Included adverse events, mortality, dropout rates, compliance.
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Protocol also stated that EQ-5D (quality of life) and Geriatric Depression Scale will be administered at
baseline and 24 months.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Centralized telephone randomization by independent statisticians
was used with full allocation concealment and minimization for age, gender,
baseline TICS-M score and consent for MRI."
Comment: Appropriately randomised.
Allocation concealment
(selection bias)
Low risk Quote: "Centralized telephone randomization by independent statisticians
was used with full allocation concealment and minimization for age, gender,
baseline TICS-M score and consent for MRI."
Comment: Appropriate allocation concealment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Participants, study partners, and those assessing outcomes were blind
to the assignment of intervention". "The placebo group received vitamin-free
tablets of similar appearance".
Comment: Measures taken to blind participants and personnel.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Participants, study partners, and those assessing outcomes were blind
to the assignment of intervention".
Comment: Blinded outcome assessment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Of the 266 participants starting the intervention, 223 participants
(83.8%) completed the second visit 2 years later". Total withdrawals of 20 par-
ticipants (15%) from placebo group and 23 participants (17.3%) from active
treatment group.
"Fewer clinical measures at follow-up (n = 191) compared with cognitive mea-
sures (n = 223) due to some study partners being unavailable to complete the
CDR and IQCODE".
Comment: Loss to follow-up < 20% over 24 months and well balanced between
groups.
Selective reporting (re-
porting bias)
High risk Cognitive results reported were a subgroup of those specified in the proto-
col, considered by the authors to be "representative of particular cognitive do-
mains important in MCI."
Diagnosis of dementia by DSM-IV and EQ-5D (quality of life) not reported.
Cognitive results were reported by subgroups of participants with high or
low tHcy rather than as an overall effect; not specified in analysis plan in
published protocol (journals.plos.org/plosone/article?id=10.1371/jour-
nal/pone.0012244#s5).
Other bias Low risk No other risks identified.
de Jager 2012  (Continued)
 
 
Methods 3-arm, parallel group, randomised, placebo-controlled trial, 24 week's duration.
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Participants Location: The Netherlands.
Setting of recruitment and treatment: Free-living older persons and older persons living in care-facil-
ity homes, recruited via mailed health questionnaires.
Sample size
• Number randomised: 195, of whom 119 had CDR 0 at baseline and were included in this review: 38
in vitamin B12 group, 38 in vitamin B12 + folic acid group, 43 in placebo group.
"Randomization was stratified according to MMA concentration at the screening visit (< and > 0.45
µmol/L), age (< and > 80), sex and MMSE score (< and > 24 points)."
Participant baseline characteristics:
• Age in years (mean ± SD) : vit B12 80.42 ± 5.52, vit B12 + FA 80.82 ± 4.18, placebo 79.86 ± 4.74.• Female sex
: vit B12 29/38 (76%), vit B12 + FA 29/38 (76%), placebo 34/43 (79%).• Cognitive function - MMSE score (mean ± SD): vit B12 28.18 ± 1.43, vit B12 + FA 28.34 ± 1.40, placebo
27.93 ± 1.80.
Inclusion criteria:
• Aged ≥ 70 years.• Mild vitamin B12 deficiency defined as (1) a serum vitamin B12 concentration between 100 and 200
pmol/L, or (2) a serum vitamin B12 concentration between 200 and 300 pmol/L.• Plasma MMA concentration ≥ 0.32 μmol/L.• Serum creatinine concentration ≤ 120 μmol/L.• Ingested 90% or more of capsules during a 2-week placebo run-in period prior to randomisation.
Exclusion criteria:
• History of cobalamin deficiency.• Use of cobalamin (> 50 µg/day) or folic acid (> 200 µg/day).• Surgery or diseases of the stomach or small intestine, anaemia, dementia, life-threatening diseases,
or severe hearing or visual problems
Interventions Intervention:
1) Vitamin B12: 1000 µg vitamin B12 (cyanocobalamin) per day orally for 24 weeks.
2) Vitamin B12 and folic acid: 1000 µg vitamin B12 (cyanocobalamin) plus 400 µg folic acid per day oral-
ly for 24 weeks.
Comparator:
Placebo capsule.
The placebo capsules contained AVICEL PH102 (Medipulp GmbH, Aschaffenburg, Germany) as a filler.
Use of additional interventions (common to both treatment arm): not reported.
Outcomes Cognitive function
Cognitive function was assessed before and after 24 wk of treatment with the use of an extensive neu-
ropsychologic test battery that included the domains of attention, construction, sensorimotor speed,
memory, and executive function.
Cognitive function was assessed by 6 trained and registered neuropsychologists during the run-in peri-
od (baseline) and at week 24 of the intervention during a 1.5 to 2 hour session.
Neuropsychological test battery included:
Eussen 2006  (Continued)
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• finger tapping, computerised;• motor planning 2 and 3, computerised;• Figure of Rey copy, immediate recall and delayed recall;• 15 word learning immediate recall, delayed recall and recognition;• Trail-making test, part A and part B;• Digit span forward and backward;• Raven Progressive Matrices;• Stroop test;• Similarities, WAIS;• Word fluency, letter;• Word fluency, animals.
Depression measured with Geriatric Depression Scale
Biochemical measures: vitamin B12, methylmalonic acid, holotranscobalamin, homocysteine, red
blood cell folate.
Source of Funding Study supported by grants from ZON-MW, The Hague, Netherlands; Kellogg's Benelux, Zaventem, Bel-
gium; Foundation to Promote Research into Functional Vitamin B12 Deficiency and the European
Union BIOMED Demonstration Project; Nutricia Health Foundation, Wageningen, Netherlands.
Declaration of Interest  
Notes Compliance was checked by counting the number of unused capsules remaining in capsule dispensers
and by verifying pill counts in the participants’ diaries. Mean compliance was 99%.
Professor Simone Eussen and Professor Lisette de Groot kindly provided data separately on partici-
pants with CDR 0.5 at baseline for inclusion in this review.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomized", no further information.
Allocation concealment
(selection bias)
Unclear risk No information.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quotes: "The capsules given to the separate treatment groups were identical
in appearance, smell and taste." "The study had a double-blind design."
Comment: participants and personnel blind to allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The study had a double-blind design." No specific mention of outcome
assessors.
Comment: outcome assessors probably blind to allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Incomplete outcome data varied between cognitive tests. For included out-
comes, data available for minimum of 82% of participants.
In study as a whole, "16% ... were unable to complete the trial, mostly because
of illness, and the dropout rate was slightly higher in the vitamin B12 + folic
acid group than in the other groups." Dropout in whole study: 10/64 B12, 15/66
B12 + folic acid, 8/65 placebo.
Comment: major effect of differential dropout unlikely.
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Selective reporting (re-
porting bias)
Low risk All outcomes mentioned in methods fully reported.
Other bias Low risk No other biases identified.
Eussen 2006  (Continued)
 
 
Methods 2-arm, parallel group, randomised, controlled trial, 6 months duration.
Participants Location: China, Shandong (Weifang), single centre.
Setting of recruitment and treatment: community.
Sample size
• Number randomised: 40 in intervention, 40 in comparator.• Number completed: 38 in intervention, 37 in comparator.
Participant baseline characteristics:
• Age in years (mean ± SD) : intervention 65.45 ± 2.89, comparator 66.37 ± 1.93.• Female sex
: intervention 20/40 (50%), comparator 22/40 (55%).• Cognitive function - MMSE score (mean ± SD): intervention 24.88 ± 0.93, comparator 24.61 ± 0.85.
Inclusion criteria:
• Complaints of memory issues by participant, family members, or others who are well-informed;• Mini-Mental State Examination (MMSE) score ≤ 26; Global Deterioration Scale (GDS) grade 2 to 3, Ac-
tivities of Daily Living (ADL) score ≤ 18;• Cognitive impairment > 3 months;• Memory test results 1.5 standards deviations below normal controls matched for age and education;• Aged 60 to 75 years.
Exclusion criteria:
• Diagnosed with dementia, or any other disease which leads to brain function disorder;• Severe disease of heart, liver, lung, kidney etc., severe anaemia, severe malnutrition, thyroid problem,
or folic acid deficiency;• Severe vision and hearing impairment;• Taken folic acid supplement within last month.
Interventions Intervention:
400 µg folic acid per day orally for 6 months.
Comparator group:
No intervention, maintenance of their usual lifestyle and eating habits.
Use of additional interventions (common to both treatment arm): not reported.
Outcomes Overall cognitive function: MMSE (also measured: MoCA).
Functional performance: Activities of Daily Living (ADL) scale.
Source of Funding Not reported.
Fan 2017 
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
42
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Declaration of Interest No declarations.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table
“按随机数字表法将受试对象随机分为对照组和⼲预组，每组４０例。” (page 4161)
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded.
On the first day of each month, subjects in the experimental group were given
a bottle of folic acid (400μg/tablet, 30 tablets/bottle) by research sta% in com-
munity. They were instructed to take one tablet per day.
Research sta% contacted participants regularly and recorded the usage of folic
acid in the intervention group. No mention of contact with comparator group.
“⼲预组每⽉第１天由社区服务站相关⼈员统⼀发放规格为每⽚４００μｇ的叶酸１瓶（３０⽚），每天服⽤１⽚，持续６个⽉，定期回访，询问叶酸服⽤情况并记录。”
“对照组不进⾏任何⼲预，维持原有的⽣活、饮⾷习惯。” (page 4161)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No information
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 75/80 (94%) completed trial. 3 dropped out in control arm, and 2 dropped out
in intervention arm. 2 cases excluded for missing more than 5 doses, 3 cases
voluntary dropout, group allocations not reported. Results reported only for
the 75 participants who completed the trial.
Selective reporting (re-
porting bias)
Low risk Results were reported for all outcomes mentioned in the Methods section of
paper. No protocol identified.
Other bias Low risk No other sources of bias identified.
Fan 2017  (Continued)
 
 
Methods 2-arm, placebo-controlled, randomised, controlled trial, duration 12 weeks
Participants Location: Cincinnati, Ohio, USA. Single centre.
Setting of recruitment and treatment: Recruitment via advertisement for volunteers with mild mem-
ory problems. Study conducted at Department of Psychiatry and Neuroscience, University of Cincinnati
College of Medicine.
Sample size:
• Number randomised: 15 in intervention, 11 in comparison.
Krikorian 2010 
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• Number completed: 15 in intervention, 11 in comparison.
Participant (Baseline) characteristics:
• Age in years (mean ± SD): CrPic: 72.2 ± 7.0, placebo 69.8 ± 4.7
Inclusion criteria:
• Elderly individuals with CDR (Clinical Dementia Rating scale) classification of 0.5, indicating early
memory decline consistent with MCI.
Exclusion criteria:
• Diabetes;• Liver or kidney disease;• Substance abuse disorder;• Diagnosed with a psychiatric or neurological condition.
Interventions Active intervention:
Chromium picolinate (CrPic) containing 1000 mcg elemental chromium once daily for 12 weeks.
Comparator:
Placebo once daily.
Outcomes Outcomes of interest in the review:
Specific cognitive functioning subdomain: episodic memory: California Verbal Learning Test (CVLT)
Source of Funding Funding and material support for this research was provided by Nutrition 21, Inc., Purchase, NY, USA.
Declaration of Interest No declarations provided.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Enrolled subjects were randomly assigned in a double-blind man-
ner to receive chromium picolinate (CrPic), containing 1000 mcg elemental
chromium, or placebo for 12 weeks".
Comment: Insufficient information about sequence generation.
Allocation concealment
(selection bias)
Unclear risk Comment: Method of allocation concealment not described in the paper.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "double-blind".
Comment: Insufficient information regarding the blinding of participants and
personnel.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "double-blind"
Comment: Insufficient information in the paper for judgement on the level of
risk.
Incomplete outcome data
(attrition bias) 
Unclear risk Comment: The paper did not mention any participants lost to follow-up or
missing data.
Krikorian 2010  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk No protocol available. All outcomes mentioned in Methods section reported.
Other bias Low risk No other risks identified.
Krikorian 2010  (Continued)
 
 
Methods 2-arm, parallel group, randomised, controlled trial, 1 year duration
Participants Location: Iran. Single centre.
Setting of recruitment and treatment: Tehran University, School of Nutritional Sciences and Dietet-
ics.
Sample size:
• Number randomised: 148 in intervention, 148 in comparator (total 296).• Number completed: 127 in intervention, 129 in comparator (total 256).
Participant (baseline) characteristics:
• Age in years (mean ± SD): 66.5 ± 0.39 in vitamin supplementation group, 66.3 ± 0.38 in control group.• Sex: 53% female among study completers.
Inclusion criteria:
• MMSE scores between 21 and 26;• Minimum education to fiSh grade;• Age between 60 and 75 years.
Exclusion criteria:
• Dementia, depression, or epilepsy;• Mental retardation, history of brain surgery, or any significant neurological disease;• Severe cardiovascular disease and severe anaemia;• Severe kidney or liver disease, inflammatory intestinal disease, and any disease that interfered with
the antioxidant's absorption;• Consumption of antioxidant medication or vitamin that might modify the results;• BMI more than 30;• Special diet (vegetarian, vegan, etc.);• Smoking;• Addicted to alcohol;• Using neuroleptic drugs, benzodiazepine, immunosuppressant, anti-depression and anticonvulsants
medication;• Current medication known to influence vitamin E and C status (laxatives and hormone replacement
therapy).
Interventions Active intervention:
300 mg of vitamin E (Dl-alpha- tocopherol acetate) plus 400 mg vitamin C (ascorbic acid) daily for a
year.
Comparator:
Placebo.
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Outcomes Outcomes of interest in the review:
Overall cognitive function: MMSE.
Source of Funding This study was supported by Institute of Nutritional Sciences, University of Vienna and the Vice-chan-
cellor for Research, Tehran University of Medical Sciences (TUMS), Iran, by a Grant (No. 11126).
Declaration of Interest "The authors declare that there are no conflicts of interest".
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The MCI subjects were divided to two groups according to their gen-
der (male or female), each of them were further divided to three age groups
including 60-65, 65-70, and 70-75 years. The subjects within each of these six
groups were then further divided to two equally numbered supplemented or
placebo subgroups by simple randomization".
Comment: Insufficient information about sequence generation process.
Allocation concealment
(selection bias)
Unclear risk Comment: No information – allocation concealment not described.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Described as "double-blind".
Quote: “One group consumed 300 mg of vitamin E (Dl-alpha- tocopherol ac-
etate) plus 400 mg vitamin C (ascorbic acid) per day, and the second group
consumed placebo with the identical condition over the 1-year intervention
period".
Comment: Unclear from this whether appearance of supplements and placebo
were identical.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Evaluation of cognitive function by MMMSE was blindly performed by
an expert psychologist."
Comment: Blinded outcome assessor.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: “Of the 761 volunteers, 296 were found to have MCI and selected for the
next part of the study. From these, 40 did not continue with the study due to
the problems tolerating the supplementations (14 subjects), 1 subject died,
and 25 subjects abstained to continue participation due to personal reasons.
148 were randomised to each group and 256 subjects completed the study.”
21/148 in the vitamins group and 19/148 in the placebo group did not com-
plete.
Comment: The participants who did not complete the trial (40/296, 13.5%)
were not included in the analysis. Reason for exclusion was not described
based on the allocated group.
Selective reporting (re-
porting bias)
Low risk Comment: Outcomes specified in the methods section were reported. No ac-
cess to trial protocol.
Other bias Low risk No other risks identified.
Naeini 2014  (Continued)
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Methods 3-arm, parallel group, randomised, controlled trial, duration 3 years
Participants Location: United States and Canada.
Setting of recruitment and treatment: 69 ADCS sites in the United States and Canada, between March
1999 and January 2004.
Sample size:
• · Number randomised: 257 in intervention, 259 in comparison.• · Number completed: 185 in intervention, 193 in comparison.
Participant baseline characteristics:
• Age in years (mean ± SD): placebo 72.9 ± 7.6, vitamin E 72.8 ± 7.3.• Female sex: placebo 121 (47%), vitamin E 119 (46%).• Cognitive function - MMSE score (mean ± SD): placebo 27.35 ± 1.8, vitamin E 27.20 ± 1.9
Inclusion criteria:
• Amnestic mild cognitive impairment of a degenerative nature (insidious onset and gradual progres-
sion);• Age 55-90 years, inclusive;• Study informant available;• MMSE 24-30;• Adequate vision and hearing for neuropsychological testing;• Normal vitamin B12 level and thyroid function studies and non-reactive RPR;• Electrocardiogram normal or no clinically significant abnormalities;• CDR 0.5 - Memory box score 0.5 or 1 and No box score greater than 1;• All subjects and study informants signed.
Exclusion criteria:
• Significant cerebral vascular disease - Modified Hachinski > 4;• Depression - Hamilton Depression Rating Scale > 12;• Central nervous system infarct, infection, or focal lesions of clinical significance on CT or MRI scans;• Medical diseases or psychiatric disorders that could interfere with study participation;• Pregnant, lactating, or of child bearing potential;• Taking vitamin supplements, other supplements, or a multivitamin;• Restrictions on concomitant medication usage, including those with significant cholinergic or anti-
cholinergic effects or potential adverse effects on cognition.
Interventions Active intervention:
2000 IU of vitamin E and multivitamin containing 15 IU of vitamin E daily. Intial vitamin E dose was 1000
IU daily, increased to 2000 IU (1000 IU twice daily) after 6 weeks.
Comparator group:
Placebo vitamin E and multivitamin containing 15 IU of vitamin E daily.
Note: There was a third arm in which participants received donepezil. Both groups of interest in this re-
view received placebo donepezil.
Outcomes Outcomes of interest in the review:
Progression to possible or probable Alzheimer’s disease, defined according to the clinical criteria of the
National Institute of Neurological and Communicative Diseases and Stroke and the Alzheimer’s Disease
and Related Disorders Association.
Petersen 2005 
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Overall cognitive function: MMSE (also measured: ADAS-cog).
Specific cognitive subdomain: episodic memory: standardised composite z-score incorporating ADAS
immediate and delayed word-recall scores and the New York University immediate and delayed para-
graph-recall scores.
Specific cognitive subdomain: executive function: standardised composite z-score incorporating the
digits-backward test, Symbol Digit Modalities Test, and number-cancellation test.
Clinical global impression: CDR sum of boxes, Global Deterioration Scale.
Functional performance: ADCS Mild Cognitive Impairment Activities of Daily Living Scale.
Adverse events: rates of adverse events that occurred in at least 5% of subjects in the donepezil or vita-
min E group and at least two times in the placebo group during the double-blind phase.
Source of Funding Supported by a grant from the National Institute on Aging (UO1 AG10483) (50% of funding), and by Pfiz-
er and Eisai (50% of funding). DSM Nutritional Products donated the vitamin E.
Declaration of Interest Most authors were either employees of a pharmaceutical company funding the study, or had received
fees for various engagements from pharmaceutical companies.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "We used an adaptive allocation scheme for the treatment assignment,
with the MMSE score, age, and APOE ϵ4 status as balancing covariates.
Comment: Adequate sequence generation in the study.
Allocation concealment
(selection bias)
Low risk Comment: Insufficient information given. Should be adequate in a large multi-
centre well designed study.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “In this multicenter, randomized, double-blind, placebo-controlled,
parallel-group study, which was conducted between March 1999 and January
2004”.
Comment: Insufficient information on the process of double-blinding. Should
be adequate in a large multicentre RCT. Placebos used and identical treatment
regimens in all groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "A data and safety monitoring board reviewed the blinded safety data
every three months during the trial.".. "verification by a central review com-
mittee that a participant met these clinical criteria for Alzheimer’s disease..."
Comment: Should be adequate in a large trial with safety and central review
committees for main outcomes.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Only 185/257 (72%) in intervention and 193/259 (75%) completed review.
Comment: More than 25% dropout from each arm.
Selective reporting (re-
porting bias)
High risk No protocol identified. Cognitive results reported as composite z-scores, indi-
vidual test results not reported. Number of participants in each analysis not re-
ported.
Other bias Low risk No other potential biases detected.
Petersen 2005  (Continued)
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Methods Substudy of the VITATOPS trial, a randomised, 2-arm, parallel group, placebo-controlled trial.
Participants Location: VITATOPS was an international, multicentre (20 countries from 4 continents). This substudy
took place in a single study centre of the VITATOPS trial in Singapore.
Sample size
Number randomised: 8164 participants with recent stroke or TIA randomised in VITATOPS. This sub-
study was of the 230 subjects with recent lacunar stroke and cognitive impairment no dementia (CIND).
118/230 allocated to B vitamins, 112/230 allocated to placebo.
Participant baseline characteristics:
• Age in years (mean (range)): 67 (61-73)• Female sex: 39.6%• Cognitive function - MMSE score (median (IQR)): B vitamins 24 (22-27), placebo 25 (21-27).
Inclusion criteria: "patients presenting within 7 months of stroke (ischaemic or haemorrhagic) or TIA
(eye or brain), as defined by standard criteria, are eligible" for VITATOPS. For this substudy, which took
place in a single VITATOPS centre, "patients with recent lacunar stroke and cognitive impairment no
dementia (CIND) who were followed up every 6 months for 1 to 5 years as per VITATOPS trial protocol
were included. CIND was defined as impairment in at least one domain of the neuropsychological test
battery using education adjusted cut-o% values of 1.5 SDs below the established normal means on indi-
vidual tests." Patients who consented for extended cognition study.
Exclusion criteria:
• Taking folic acid or vitamin B6 on medical advice;• Taking methotrexate for any reason;• Pregnant or at risk of pregnancy;• Limited life expectancy.
Interventions Intervention:
Folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 μg once daily.
Comparator:
Placebo.
Outcomes "Neuropsychological tests results focusing on attention and executive functions derived from a stan-
dardized cognitive assessment battery that validated for Singaporean elderly was analysed."
Standardized MMSE;
Digit span forward;
Digit span backward;
Visual memory span forward;
Visual memory span backward;
Category naming - animals;
Digit cancellation;
Frontal assessment battery.
Other: serum homocysteine.
Ting 2017 
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
49
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Source of Funding Singapore Biomedical Research Council and Singapore National Medical Research Council.
Declaration of Interest 6/8 authors: no disclosures. "Dr Chen has received support from the Biomedical Research Council, Sin-
gapore for current study of vitamin therapy in the prevention of dementia and cognitive deterioration
following stroke from 2004 to 2008." "Dr EK Tan has received support from the National Medical Re-
search Council, Duke NUS Graduate Medical school, and has received honoraria for duties as an editor
of European Journal of Neurology (Wiley publisher) and Parkinsonism Related Disorders (Elsevier Pub-
lisher), and sponsorship from Novartis Pharmaceuticals, GSK Pharmaceuticals and Lundbeck Pharma-
ceuticals."
Notes 5 of 235 potentially eligible subjects did not consent to participate in this extended cognition substudy.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Parent study (VITATOPS), quote: "a central 24-hour telephone service or an in-
teractive website ... uses random permuted blocks stratified by hospital to al-
locate a treatment pack number."
Allocation concealment
(selection bias)
Low risk Parent study (VITATOPS), quote: "a central 24-hour telephone service or an in-
teractive website ... uses random permuted blocks stratified by hospital to al-
locate a treatment pack number."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "double-blind". Parent study (VITATOPS), quote "the tablets being ei-
ther vitamin supplements or matching placebo".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No specific information about site investigators. Likely blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk "The number of the study participants at the end of each study year from year
one till year five for active and placebo group was 97, 83, 73, 45, 33 and 93, 75,
59, 38, 27 respectively."
Selective reporting (re-
porting bias)
Unclear risk Quote: "Neuropsychological tests (sic) results focusing on attention and exec-
utive functions derived from a standardized cognitive assessment battery that
validated (sic) for Singaporean elderly was analysed." No protocol for substudy
identified. Not clear if any outcomes were measured in addition to those re-
ported.
Other bias Low risk No other sources of bias identified.
Ting 2017  (Continued)
 
 
Methods The FACT study (Folate physical Activity Cognition Trial).
2 x 2 factorial, randomised controlled trial (RCT) comparing the effects of (1) a walking programme with
a placebo activity programme, and (2) vitamin B supplementation with placebo supplementation over
1 year.
Participants Location: Netherlands.
Setting of recruitment and treatment: Community setting in a Dutch town.
van U:elen 2008 
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Sample size:
• Number randomised: 90 in intervention, 89 in comparison.• Number completed: 71 in intervention, 67 in comparison.
Participant baseline characteristics:
• Age (mean (SD)): Men vitamin B (n = 44) = 75 (2.7); Men placebo (n = 41) = 74 (2.9); women vitamin B
(n = 34) = 76 (2.9); women placebo (n = 33) = 76 (2.9).• MMSE (median (25th–75th percentile): Men vitamin B (n = 44) = 28 (28–29); men placebo (n = 41) = 29
(28–29); women vitamin B (n = 34) = 29 (29–30); women placebo (n = 33) = 29 (28–30).
Inclusion criteria:
• Memory complaints (answer ‘‘yes’’ to question ‘‘do you have memory complaints’’, or at least twice
answering ‘‘sometimes’’ on the Strawbridge cognition scale 26);• Objective memory impairment (10 WLT delayed recall ≤5 and percentage savings ≤100));• Normal general cognitive function (TICS ≥ 19 and MMSE ≥ 24);• Intact daily functioning (no report of disability in activities of daily living on GARS scale 30 except on
the item ‘‘taking care of feet and toe nails’’);• Absence of dementia;• Being able to perform moderate intensity physical activity without making use of walking devices —
for example, a rollator or a walking frame.
Exclusion criteria:
• Using vitamin supplements/vitamin injections/drinks with folic acid, vitamins B-12 and B-6, compa-
rable to the vitamin supplement given in the intervention;• Suffering from epilepsy, multiple sclerosis, Parkinson’s disease, kidney disorder requiring haemodial-
ysis, psychiatric impairment;• Suffering from depression as measured by the Geriatric Depression Scale (cut o% (5));• Using medication for rheumatoid arthritis or psoriasis which interfered with the vitamin supplement;• Alcohol abuse (men 21 drinks a week, women 15 drinks a week);• Currently living in a nursing home or on a waiting list for a nursing home.
Interventions Active intervention:
5 mg folic acid, 0.4 mg vitamin B-12 (cyanocobalamin) and 50 mg vitamin B-6 (pyridoxine hydrochlo-
ride) once daily for a year.
Comparator:
Placebo.
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: MMSE;
Specific cognitive functioning subdomain: episodic memory: Auditory Verbal Learning Test (AVLT);
Specific cognitive functioning subdomain: executive functioning: Stroop Colour Word Test-Abridged
(SCWT-A), (also measured: letter fluency);
Specific cognitive functioning subdomain: speed of processing: Digit Symbol Substitution Test (DSST);
Quality of life: Dementia - quality-of-life (D-QOL), (also measured: health-related QoL with SF-12);
Adverse events.
Source of Funding Funded by Body@Work, Research Center Physical Activity, Work and Health, TNO-VU University Med-
ical Center. External financial support was obtained from the municipality of Alkmaar and the ‘‘Sticht-
ing Fonds voor het Hart’’.
van U:elen 2008  (Continued)
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VIATRIS provided the FA/B12/B6 pills and placebo pills.
Declaration of Interest "None of the external sources had input into protocol development, data collection, analyses, and in-
terpretation or drafting this manuscript.
Notes International Standard Randomised Controlled Trial Number Register (ISCTRN) 19227688
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: After the baseline interview, participants were randomised using the
option ‘‘random sample of cases’’ in SPSS.
Comment: Computer software used for randomisation leading to adequate se-
quence generation in the study.
Allocation concealment
(selection bias)
Unclear risk Quote: "Participants and exercise instructors were blinded to group allocation
by being leS unaware of which exercise programme was supposed to be effec-
tive. The pills were coded as A or B by the manufacturer. The key was decoded
after data analysis".
Comment: Further information required.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Pills were coded A or B by manufacturer and then decoded only after
data analysis".
Comment: Participants and personnel were blinded to the intervention a par-
ticipant received.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All cognitive outcome measures were assessed by trained examiners,
who were also blinded to group allocation".
Comment: Low risk of detection bias as the examiners were blinded to group
allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "For both interventions, data were analysed on a modified inten-
tion-to-treat basis, including participants with at least one post-baseline as-
sessment".
Comment: All participants accounted for and data analysed from all partici-
pants with an intention-to-treat method.
Selective reporting (re-
porting bias)
Low risk Quote: "The walking program and/or FA/B12/B6 supplementation were not ef-
fective in improving cognition within one year".
Comment: The only outcome measure tested was cognitive function and this
was included in the results.
Other bias Low risk No other potential biases detected.
van U:elen 2008  (Continued)
AD: Alzheimer's disease
ADAS-cog: Alzheimer's Disease Assessment Scale - cognitive
ADCS: Alzheimer's Disease Cooperative Study
ADL: Activities of Daily Living
APOE ϵ4: Apolipoprotein-E gene, ϵ4 allele
AVLT: Auditory Verbal Learning Test
CAMDEX: Cambridge Mental Disorders of the Elderly Examination
CDR: Clinical Dementia Rating scale
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CIND: Cognitive Impairment - no dementia
CLOX: Clock drawing executive test
CrPic: Chromium picolinate
CT: Computerised tomography
CVLT: California Verbal Learning Test
D-QOL: Dementia Quality of Life questionnaire
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
DSST: Digit Symbol Substitution Test
EQ-5D: Euroqol-5D: a standardized instrument for use as a measure of health outcome
FA: Folic acid
GARS: Groningen Activity Restriction Scale
HVLT: Hopkins Verbal Learning Test
holoTC: Holotranscobalamin
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly
IQR: Interquartile range
ISRCTN: International Standard Randomised Controlled Trial Number
MCI: Mild cognitive impairment
MMA: Methylmalonic acid
MMSE: Mini-Mental State Examination
MoCA: Montreal Cognitive Assessment
MRI: Magnetic resonance imaging
PAL: Paired Associate Learning
QoL: Quality of life
RBC: Red blood cell
SCWT-A: Stroop Color-Word Test - Abridged
SDMT: Symbol Digit Modalities Test
SF-12: 12-item Short Form Survey
TIA: Transient Ischaemic Attack
TICS28: 28-item Telephone Interview for Cognitive Status
TICSm: Modified Telephone Interview for Cognitive Status
vit: vitamin
WAIS: Wechsler Adult Intelligence Scale
wk: week
10 WLT: 10 Word Learning Test
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abbasi 2013 No cognitive outcomes.
Anand 2011 Wrong population. Participants cognitively healthy.
Andreeva 2011 Wrong population. Participants cognitively healthy.
Anonymous 2008 Wrong design. Not an RCT.
Arwert 2003 Ineligible intervention. Duration of intervention three weeks.
Benton 1995 Wrong population. Participants cognitively healthy.
Bryan 2002 Ineligible intervention. Duration of intervention five weeks.
Chan 2010 Ineligible intervention. Combined amino acids and vitamins.
Chandra 2001 Other reason: retracted report.
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Study Reason for exclusion
Clarke 2003 Wrong population. Approximately 2/3 of participants had a diagnosis of dementia.
Cockle 2000 Wrong population. Participants cognitively healthy.
Corless 1987 Wrong population.
Dangour 2011 Wrong population. Participants were cognitively healthy.
Durga 2007 Wrong population. Participants were cognitively healthy.
Ford 2008 Wrong population. Participants were cognitively healthy.
Ford 2010 Wrong population. Participants were cognitively healthy.
Grodstein 2007 Wrong population. Participants were cognitively healthy.
Grodstein 2013 Wrong population. Participants were cognitively healthy.
Hankey 2013 Wrong population. Participants were cognitively healthy (after stroke).
Harris 2012 Wrong intervention: included probiotics and herbal extracts.
Heart Protection Study Collab-
orative Group 1999
Wrong population. Participants were cognitively healthy.
Hvas 2004 Wrong intervention. Duration of intervention was four weeks; administered parenterally.
Kang 2006 Wrong population. Participants were cognitively healthy.
Kang 2008 Wrong population. Participants were cognitively healthy.
Kang 2009 Wrong population. Participants were cognitively healthy.
Kesse-Guyot 2011 (SUVIMAX
trial)
Wrong population. Participants were cognitively healthy.
Kryscio 2017 Wrong population. Participants were cognitively healthy.
Kwok 2011 Wrong population. Participants had dementia.
Kwok 2017 Wrong population: Participants were mixed population with CDR 0 or CDR 0.5 at baseline.
Lewerin 2005 Wrong population. Participants were cognitively healthy.
Loriaux 1985 Ineligible intervention. Duration of treatment was eight weeks.
Macpherson 2012 Wrong population: elderly women who responded 'yes' to the single question "Do you feel like your
memory is getting worse?" Wrong intervention: "multivitamin, antioxidant and mineral formula
with added herbal and antioxidant plant extracts."
Maniam 2004 Wrong population: probably healthy older people. Only an abstract has been published since 2004.
Maylor 2006 (ZENITH study) Wrong population. Participants were cognitively healthy.
McMahon 2006 Wrong population. Participants were cognitively healthy.
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Study Reason for exclusion
McNeill 2007 Wrong population. Participants probably mainly cognitively healthy although no baseline assess-
ment conducted.
Murray-Kolb 2011 Wrong population. Participants were cognitively healthy.
NCT00903695 Wrong intervention. Intervention consisted of vitamins and amino acids.
NCT01095211 Wrong intervention. Duration of Intervention 45 days.
NCT01317849 Withdrawn (status posted on ClinicalTrials.gov on August 20, 2014)
NCT01708005 Wrong intervention. Intervention contained PUFAs and grape extract as well as vitamins and miner-
als.
NCT02467153 Wrong outcomes.
Pase 2015 Wrong intervention. Intervention included fatty acids.
Pathansali 2006 Wrong population. Participants were cognitively healthy.
Wrong intervention. Duration of treatment four weeks.
Rietsema 2014 Wrong design. Case report.
Rossom 2012 Wrong population. Participants were cognitively healthy.
Sanchez 2011 Wrong population. Participants were "apparently healthy", mean MMSE 26.7 ± 2.7.
Satalich 2014 Wrong design.
Smith 1999 Wrong population: excluded if MMSE < 18, but no information on mean MMSE; likely to have includ-
ed healthy participants and participants with dementia.
Summers 2010 Wrong intervention. Intervention included components other than vitamins and minerals.
van der Zwaluw 2014 Wrong population. Participants were cognitively healthy.
Walker 2012 Wrong population. Participants were cognitively healthy.
Wolters 2005 Wrong population. Participants were cognitively healthy.
Wouters-Wesseling 2005 Wrong intervention. Intervention included components other than vitamins and minerals.
Ya%e 2004 Wrong population. Participants were cognitively healthy.
CDR: Clinical Dementia Rating scale
MMSE: Mini-Mental State Examination
PUFA: Polyunsaturated Fatty Acid
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised placebo controlled trial.
ACTRN12607000321448 
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Participants Location: Australia. Single centre.
Setting of recruitment and treatment: WA Centre for Health & Ageing, University of Western Aus-
tralia.
Inclusion criteria:
• Adults with mild cognitive impairment (-1.5 standard deviations below norm on any task in the
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological battery);• Over 65 years of age;• Vitamin D concentration between 12.5 and 50 nmol/L at baseline.
Exclusion criteria:
• · Diagnosis of osteoporosis requiring treatment;• · No informant available;• · Severe physical or medical illness that would preclude completion of the trial;• · Hearing or visual impairment that would preclude assessments;• Already in an intervention trial;• · Clinical history of stroke;• · Fall in the last 3 months;• · Heart attack in the last 3 months;• · Fall with fracture over the age of 65 years;• · History of kidney or bladder stones;• · Current acute depression;• · History of schizophrenia;• · Current diagnosis of dementia.
Interventions Intervention :
1000 IU vitamin D daily by oral tablet.
Comparator group:
Placebo (soyabean oil tablet indistinguishable from active tablet).
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: Cambridge Examination for Mental Disorders in the Elderly - Cogni-
tive section (CAMCOG);
Specific cognitive functioning subdomain: executive function: digit-symbol coding task;
Specific cognitive functioning subdomain: episodic memory: California Verbal Learning Scale-Re-
vised;
Development of dementia;
Quality of life: SF-12.
Reason awaiting classification Only publication of baseline results and protocol found. No results available after contact with au-
thors.
Notes National Health and Medical Research Council Dementia Research Grants Program
ACTRN12607000321448  (Continued)
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Methods Randomised controlled trial. No information on randomisation methods.
Participants "120 patients with VCIND complicated by HHcy were randomly selected". All were "patients with
cerebral apoplexy that received treatment at the First Hospital Affiliated to the Chinese PLA Gener-
al Hospital".
Interventions Experimental intervention: "5 mg of extra folic acid per day and 500 mcg of mecobalamin thrice per
day for 24 weeks, apart from conventional treatment."
Control group: presumed conventional treatment only (not specified).
Outcomes Montreal Cognitive Assessment (MoCA)
Reason awaiting classification Multiple pieces of information sought from authors about methods and results. Unusual age profile
of participants. First email sent 19/05/17. No response received by 23/05/18.
Notes  
Jiang 2014 
 
 
Methods Randomised controlled trial. No information on randomisation methods other than "random clus-
ter sampling."
Participants 180 community-dwelling people with MCI (modified Petersen's criteria) in the Binhai New District,
Tainjin, China.
Interventions Experimental intervention: Folic acid 400 mcg daily. Control intervention: conventional treatment.
Outcomes Chinese version of Wechsler Adult Intelligence Scale - Revised (WAIS-RC).
Reason awaiting classification Multiple pieces of information sought from authors about methods, sample size, and results. No re-
sponse received by 23/05/18.
Notes Outcomes at different time points (6, 12, and 24 months) are reported in three separate papers.
Ma 2017 
CAMCOG: Cambridge Cognition Examination
HHcy: high homocysteine
MCI: Mild cognitive impairment
MoCA: Montreal cognitive assessment
SF-12: 12-item Short Form Survey
VCIND: Vascular cognitive impairment (no dementia)
WAIS-RC: Wechsler Adult Intelligence Scale - Revised (China)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Effect of vitamin D on cognitive decline of patients with memory complaint (trial short name = D-
COG).
Methods RCT, triple-blind.
Participants Aged 60+; both genders; "report to a memory centre with symptoms of memory complaint"; MMSE
score "> the 5th percentile for sociocultural level of the patient", no dementia.
NCT02185222 
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Interventions Experimental: Cholecalciferol 100 000 IU per month as a single dose, administered as oral solution.
Control: placebo. Duration: 2 years.
Outcomes Primary outcome: change from baseline on total recall test from Free and Cued Selective Remind-
ing Test.
Secondary outcomes: multiple general and domain-specific cognitive tests; all adverse events; sev-
eral biochemical outcomes.
Starting date July 2014
Contact information Sponsored by University Hospital, Tours. Contact fanny.hennekinne@univ-tours.fr
Notes Estimated completion date July 2018.
NCT02185222  (Continued)
MMSE: Mini-mental state examination
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   B vitamins versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive function (MMSE) 3 488 Mean Difference (IV, Random, 95% CI) 0.44 [-0.23, 1.12]
2 Episodic memory 3 397 Std. Mean Difference (IV, Random, 95%
CI)
0.09 [-0.10, 0.29]
3 Executive function 3 392 Std. Mean Difference (IV, Random, 95%
CI)
0.03 [-0.23, 0.29]
4 Speed of processing 2 173 Std. Mean Difference (IV, Random, 95%
CI)
0.04 [-0.26, 0.34]
5 Quality of life (D-QOL) 1 138 Mean Difference (IV, Random, 95% CI) 0.0 [-0.10, 0.10]
6 Functional performance (ADL) 1 75 Mean Difference (IV, Random, 95% CI) -0.78 [-1.35, -0.21]
 
 
Analysis 1.1.   Comparison 1 B vitamins versus placebo, Outcome 1 Overall cognitive function (MMSE).
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
de Jager 2012 110 27.9 (2.2) 113 27.7 (2.3) 30.09% 0.2[-0.39,0.79]
Fan 2017 38 26 (1) 37 24.9 (1.2) 32.05% 1.14[0.63,1.65]
Ting 2017 97 0 (0.5) 93 -0 (0.8) 37.86% 0.05[-0.13,0.24]
   
Total *** 245   243   100% 0.44[-0.23,1.12]
Favours placebo 21-2 -1 0 Favours B vitamins
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Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0.31; Chi2=15.73, df=2(P=0); I2=87.29%  
Test for overall effect: Z=1.29(P=0.2)  
Favours placebo 21-2 -1 0 Favours B vitamins
 
 
Analysis 1.2.   Comparison 1 B vitamins versus placebo, Outcome 2 Episodic memory.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
de Jager 2012 110 7.4 (3.5) 113 6.9 (3.5) 57.19% 0.14[-0.12,0.4]
Eussen 2006 26 3.5 (2.8) 10 2.6 (3) 7.35% 0.31[-0.42,1.04]
van Uffelen 2008 71 5.2 (2.9) 67 5.3 (2.6) 35.46% -0.02[-0.36,0.31]
   
Total *** 207   190   100% 0.09[-0.1,0.29]
Heterogeneity: Tau2=0; Chi2=0.94, df=2(P=0.62); I2=0%  
Test for overall effect: Z=0.93(P=0.35)  
Favours placebo 21-2 -1 0 Favours B vitamins
 
 
Analysis 1.3.   Comparison 1 B vitamins versus placebo, Outcome 3 Executive function.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
de Jager 2012 110 13.1 (1.9) 113 12.7 (2.1) 50.79% 0.2[-0.06,0.46]
Eussen 2006 21 -2.6 (1.2) 10 -2.3 (0.6) 10.63% -0.32[-1.07,0.44]
van Uffelen 2008 71 -60.9 (23.8) 67 -58.8 (19) 38.58% -0.09[-0.43,0.24]
   
Total *** 202   190   100% 0.03[-0.23,0.29]
Heterogeneity: Tau2=0.02; Chi2=2.87, df=2(P=0.24); I2=30.37%  
Test for overall effect: Z=0.24(P=0.81)  
Favours placebo 21-2 -1 0 Favours B vitamins
 
 
Analysis 1.4.   Comparison 1 B vitamins versus placebo, Outcome 4 Speed of processing.
Study or subgroup Experimental Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Eussen 2006 24 90 (56) 11 84.9 (39.5) 17.94% 0.1[-0.62,0.81]
van Uffelen 2008 71 36.4 (11.5) 67 36.1 (8.8) 82.06% 0.03[-0.3,0.36]
   
Total *** 95   78   100% 0.04[-0.26,0.34]
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.87); I2=0%  
Test for overall effect: Z=0.27(P=0.79)  
Favours placebo 10.5-1 -0.5 0 Favours B vitamins
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Analysis 1.5.   Comparison 1 B vitamins versus placebo, Outcome 5 Quality of life (D-QOL).
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
van Uffelen 2008 71 3.5 (0.3) 67 3.5 (0.3) 100% 0[-0.1,0.1]
   
Total *** 71   67   100% 0[-0.1,0.1]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours placebo 21-2 -1 0 Favours B vitamins
 
 
Analysis 1.6.   Comparison 1 B vitamins versus placebo, Outcome 6 Functional performance (ADL).
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Fan 2017 38 15.9 (1.2) 37 16.7 (1.3) 100% -0.78[-1.35,-0.21]
   
Total *** 38   37   100% -0.78[-1.35,-0.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.66(P=0.01)  
Favours B vitamins 52.5-5 -2.5 0 Favours placebo
 
 
Comparison 3.   Vitamins E and C versus placebo
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Overall cognitive function (MMSE) 1 256 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.25, 0.71]
 
 
Analysis 3.1.   Comparison 3 Vitamins E and C versus placebo, Outcome 1 Overall cognitive function (MMSE).
Study or subgroup Vitamins E + C Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Naeini 2014 127 26.8 (1.9) 129 26.6 (2) 100% 0.23[-0.25,0.71]
   
Total *** 127   129   100% 0.23[-0.25,0.71]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Favours placebo 21-2 -1 0 Favours vitamins E + C
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Appendix 1. Biological plausibility of Vitamins and Minerals
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Supplement* Summary of ac-
tion
Biological plausibility
Vitamins    
Vitamin A antioxidant;
anti-inflammato-
ry;
anti-
cholinesterase;
beta-amyloid inhi-
bition
Carboxylic form of Vitamin A known as all-trans retinoic acid has been shown to have
memory restorative function and it may be attributed to its anticholinesterase, antioxida-
tive and antiinflammatory potential (Sodhi 2013). Vitamin A and beta-carotene may also
inhibit the formation, extension, and destabilising effects of beta-amyloid fibrins. Plasma
or cerebrospinal fluid concentrations of vitamin A and beta-carotene have been reported
to be lower in AD patients, and increased Vit A/beta-carotene concentrations have been
clinically shown to slow the progression of dementia (Ono 2012).
Vitamin D neuronal activity Vitamin D receptor (VDR) and 1, alpha-hydroxylase, the terminal calcitriol-activating en-
zyme, are distributed throughout both the foetal and adult brain. This is thought to play
a role in brain development and critical brain functions (McCann 2008). Significant corre-
lation between serum 25(OH)D levels and cognitive scores were reported in De Luca 1975
and Przybelski 2007.
Vitamin E antioxidant;
beta-amyloid inhi-
bition
Vitamin E consists of a group of tocopherols and tocotrienols. Apart from lipid antioxi-
dant activity, other functions include membrane stabilisation by forming complexes with
the products of lipid hydrolysis (Wang 2000). It has been shown that the antioxidant and
free radical scavenging activity of Vitamin E inhibits amyloid beta protein-induced neu-
ronal cell death and may have implication in prevention and treatment of Alzheimer’s de-
mentia. (Behl 1992).
Vitamin K neuronal activity Vitamin K participates in the synthesis of sphingolipids. Sphingolipids participate in im-
portant cellular events such as proliferation, differentiation, senescence, and cell-cell in-
teractions. Sphingolipid metabolism has been linked to age-related cognitive decline and
neurodegenerative diseases such as Alzheimer's disease (Ferland 2012). A cross-sectional
study found correlations between higher serum phylloquinone concentration and better
cognitive scores in tests evaluating episodic verbal memory among healthy older adults
(Ferland 2013).
Thiamine
(Vitamin B1)
neuronal activity Thiamine is required as a cofactor in the cellular production of energy and enhances nor-
mal neuronal activities (Osiezagha 2013). Rats with an episode of induced thiamine defi-
ciency had cognitive, learning, and memory impairments (Langlais 1995).
Riboflavin
(Vitamin B2)
neuronal activity Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine) is water-soluble. Symptoms of neurode-
generation and peripheral neuropathy in riboflavin deficiency have been documented in
animal studies, but not observed in humans. Subclinical riboflavin deficiency may con-
tribute to increased concentrations of plasma homocysteine and may be associated with
increased risk of cardiovascular disease and impaired handling of iron (Powers 2003).
Niacin
(Vitamin B3)
vascular:
anti-inflammatory
Niacin is a water-soluble precursor cofactor essential for the formation of dozens of en-
zymes. Niacin decreases atherosclerosis development mainly by reducing LDL choles-
terol. It also has modest HDL-cholesterol-raising and anti-inflammatory effects (Kühnast
2013).
Niacin deficiency causes pellagra. Its neuropsychiatric symptoms are similar to those in
Alzheimer's disease or vascular dementia (Amanullah 2010).
Vitamin B6
(Pyridoxine, pyri-
doxal, pyridoxam-
ine, Pyridoxal 5'
homocysteine;
neuronal activity
Vitamin B6 is a group of water-soluble compounds (vitamers). Pyridoxal 5' phosphate
(PLP) and pyridoxamine 5' phosphate (PMP) are the active coenzyme forms of vitamin B6
(ODS 2014).
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phosphate (PLP)
and pyridoxam-
ine 5' phosphate
(PMP), Pyridox-
ine 5'-phosphate
(PNP))
Vitamin B6 has many important brain functions such as biosynthesis of neurotransmitters
(GABA, dopamine, noradrenaline, serotonin), receptor binding, macronutrient metabo-
lism, and gene expression. In a study looking at low plasma B6 levels predicting cognitive
decline and depression in at-risk individuals, low PLP status was seen as a risk factor for
cognitive decline and depression in at-risk populations (Scott 2013).
Folic Acid
(Vitamin B9)
antioxidant;
homocysteine;
neuronal activity
Folate is a cofactor and promotes the remethylation of homocysteine -- an amino acid
that can induce DNA strand breakage, oxidative stress, and apoptosis. Folate is required
for normal development of the nervous system, playing important roles regulating neuro-
genesis and programmed cell death. Folate deficiency and its resultant increase in homo-
cysteine levels has been linked to several neurodegenerative conditions, including stroke,
Alzheimer's disease, and Parkinson's disease (Mattson 2003).
Vitamin B12
(cobalamins:
cyanocobalamin,
hydroxocobal-
amin, methyl-
cobalamin, hy-
droxocobalamin)
homocysteine;
neuronal activity
Vitamin B12 acts as a coenzyme in metabolism of amino acids and fatty acids required
for the synthesis of nucleic acids, erythrocytes, and in the maintenance of myelin (Pawlak
2014). Lower vitamin B12 status has been associated with increased rates of cognitive de-
cline and dementia (Clarke 2007; O'Leary 2012).
Pantothenic Acid
(Vitamin B5)
energy metabo-
lism
Pantothenic acid (PA) is a component of coenzyme A, an essential cofactor in fatty acid
oxidation, lipid elongation, and fatty acid synthesis (Kelly 2011). This may have an indi-
rect effect in cognition.
Biotin
(Vitamin H)
energy metabo-
lism
Biotin is also known as Vitamin H and is part of the B complex group of vitamins. They act
as cofactors in carboxylase enzymes, fatty acid, and amino acid metabolism. This may
have an indirect effect in cognition.
Vitamin C antioxidant Vitamin C has antioxidant functions and is required for the synthesis of noradrenaline
from dopamine. It has been reported that Vitamin C levels have been lower than controls
in patients with senile dementia of Alzheimer’s type (Jeandel 1989). In a longitudinal and
cross-sectional study, it was found that higher vitamin C levels were associated with bet-
ter memory performance (Perrig 1997).
Minerals    
Calcium neuronal activity Calcium ions regulate a number of physiological processes including neuronal gene ex-
pression and the neuronal secretion of neurotransmitters (Dolphin 2012; Linus Pauling In-
stitute). Supplementation with calcium together with vitamin D was found to have no sig-
nificant association with incident cognitive impairment (Rossom 2012).
Ozawa 2012 concluded that, in the general Japanese population, higher self-reported di-
etary intakes of potassium, calcium, and magnesium reduced the risk of all-cause demen-
tia, especially Vascular Dementia (VaD). The proposed mechanism was through the re-
duction of vascular risk factors.
Chromium energy produc-
tion; metabolism.
Chromium is needed for energy production and has been found to promote the effect of
insulin involved in metabolism and storage of protein, carbohydrates and lipids within
the CNS (IOM 2011; Ozawa 2012; Anderson 1997).
Chromium is involved in metabolism of nucleic acid, which is needed to build DNA, the
genetic material in cells and it promotes synthesis of cholesterol and fatty acids needed
for brain function. It may lower LDL cholesterol and triglyceride levels, raise HDL choles-
terol levels and reduce high blood pressure (Preuss 1997).
Insulin resistance is implicated in the pathophysiological changes associated with
Alzheimer's disease, and pharmaceutical treatments that overcome insulin resistance
improve memory function in subjects with mild cognitive impairment (MCI) and early
  (Continued)
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Alzheimer's disease. Chromium (Cr) supplementation improves glucose disposal in pa-
tients with insulin resistance and diabetes. A double-blind RCT suggested that supple-
mentation with chromium picolinate can enhance cognitive inhibitory control and cere-
bral function in older adults at risk for neurodegeneration (Krikorian 2010). A positive cor-
relation between cognitive function and serum chromium levels was found in a study
(Smorgon 2004).
Copper antioxidant Copper is a component of an antioxidant enzyme called superoxide dismutase that pro-
tects cells from damage by harmful free radicals. Copper is necessary for a healthy nerve
system and taste sensitivity (IOM 2011).
Copper may promote non-amyloidogenic processing of amyloid precursor protein (APP)
and thereby lowers the Aβ production in cell culture systems, and it increases lifetime
and decreases soluble amyloid production in APP transgenic mice (Borchardt 1999). In
Alzheimer patients, the decline of Aβ levels in CSF is diminished in the treatment group
(Kaden 2011).
Iodine neuronal activity Iodine is needed for the synthesis of thyroid hormones, which, in turn, are needed for
the myelination of the central nervous system. Iodine is necessary for the normal devel-
opment of the brain. A deficiency of this mineral during critical periods of development
in gestation can lead to intellectual disability and neurodevelopmental problems (Bath
2013a).
Positive association was found between maternal iodine status and child IQ at age 8 years
and reading ability at age 9 years (Bath 2013b).
Iron neuronal activity Iron is needed for development of oligodendrocytes and numerous enzymes that synthe-
sise neurotransmitters such as noradrenaline, serotonin, and dopamine. It is important
for production of the haemoglobin in red blood cells (Linus Pauling Institute; IOM 2011).
Regression analysis showed that nonanaemic iron-deficient adolescent girls who re-
ceived iron performed better on a test of verbal learning and memory than girls in the
control group (Bruner 1996).
Magnesium energy, metabo-
lism
Magnesium is involved in hundreds of enzyme reactions, including those for forming
bone matrix and protein synthesis. It is vital for fat and carbohydrate metabolism, and
so plays a role in energy production; can improve insulin sensitivity in diabetics and help
regulate blood sugar level; regulates neuromuscular transmission and higher self-report-
ed dietary intakes of potassium, calcium, and magnesium reduce the risk of all-cause de-
mentia, especially VaD, in the general Japanese population (Ozawa 2012).
Manganese metabolism Manganese is needed to synthesise fatty acids and cholesterol, and metabolise carbohy-
drates and proteins. It is important for energy production. It promotes utilisation of other
key nutrients like vitamin B1 (thiamine), biotin, choline, ascorbic acid, and vitamin E (Li-
nus Pauling Institute;).
Manganese is needed for glucose metabolism, which helps regulate blood glucose. It is
needed to make manganese superoxide dismutase (MnSOD), one of the key antioxidants
that protects cells from free radical damage, and so helps maintains healthy nerves. It
works synergistically with the B-complex vitamins to generate an overall feeling of well-
being (IOM 2011).
Molybdenum metabolism Molybdenum promotes normal cell function. It functions as a cofactor for three essen-
tial enzymes that play a vital role in carbohydrate metabolism, utilisation of iron, sulphite
detoxification, and uric acid formation (Linus Pauling Institute; IOM 2011).
Phosphorus metabolism, neu-
ronal structure
and function
Phosphorus is needed for metabolism of carbohydrates and fats to produce energy and
is involved in the production of ATP required for growth and repair of cells and tissues;
needed to make cell membranes. It helps the body utilise the B-complex vitamins that
support proper muscle and nerve function (Linus Pauling Institute; IOM 2011).
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Potassium nerve transmis-
sion
Potassium is involved in regulating nerve transmissions and muscle contractions. It helps
the body handle sodium and so reduce the risk of high blood pressure (Berr 2012). It has
been found to lower the risk of stroke and ischaemic heart disease. Potassium is needed
for synthesis of protein from amino acids (Linus Pauling Institute; IOM 2011).
Higher self-reported dietary intakes of potassium, calcium, and magnesium reduce the
risk of all-cause dementia, especially VaD, in the general Japanese population (Ozawa
2012).
Selenium antioxidant Selenium is an important antioxidant especially in combination with vitamin E. It has
been found to induce repair of DNA in damaged cells (Linus Pauling Institute; IOM 2011).
Selenium is a major structural component of glutathione peroxidases which are impor-
tant antioxidant enzymes in the central nervous system and other body tissues (Mehdi
2013; Rahman 2007).
Low selenium levels were found to be related to a risk factor for cognitive function (Berr
2012; Smorgon 2004). Supplementation with selenium has been associated with an im-
proved overall health, reducing oxidative stress and ameliorating risk factors for demen-
tia (Mehdi 2013).
Sodium neuronal activity Sodium is essential for regulating muscle contractions, and nerve transmissions essential
for normal CNS physiological mechanisms and homeostasis (Linus Pauling Institute; IOM
2011).
Zinc anti-oxidant
neuronal activity
Zinc is a constituent of the antioxidant enzyme superoxide dismutase that helps reduce
the harm from harmful free radicals. Zinc regulates cell division and synthesis of genetic
cell DNA. It is essential for reproduction, repair, and normal growth within the CNS (Linus
Pauling Institute).
Zinc is found in high levels in the brain where it performs catalytic, structural, and regu-
latory roles in cellular metabolism. In the brain, zinc is bound to proteins but free zinc is
present in synaptic vesicles and performs a role in neurotransmission mediated by gluta-
mate and gamma-aminobutyric acid (GABA). Short-term deficits of zinc have been shown
to impair certain measures of mental and neurological function while long-term deficits
of zinc, especially during gestation, results in malformation or deficits in attention, learn-
ing, memory, and neuropsychological behaviour (IOM 2011)
Zinc was found to be capable of reducing post-ischaemic injury to a variety of tissues and
organs through a mechanism that might involve the antagonism of copper reactivity. Al-
though the evidence for the antioxidant properties of zinc is compelling, the mechanisms
are still unclear (Powell 2000).
* Only orally-administered supplements taken at any dose for at least 12 weeks will be included. Supplements that combine vitamins
or minerals are eligible as well.
  (Continued)
 
Appendix 2. Sources searched and search strategies
 
Source Search strategy Hits retrieved
ALOIS (www.medi-
cine.ox.ac.uk/alois)
(Date of most re-
cent search: 25
January 2018)
Basic search: VIT
(Studies within ALOIS are coded VIT if the intervention is a vitamin or mineral)
Dec 2014: 254
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
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Mar 2017: 3
Jan 2018: 1
MEDLINE In-
process and oth-
er non-indexed
citations and
MEDLINE 1950 -
present (Ovid SP)
(Date of most re-
cent search: 25
January 2018)
1. exp *Vitamins/
2. exp *Minerals/
3. exp *Dietary Supplements/
4. Calcium Carbonate/
5. vitamin*.ti,ab.
6. cholecalciferol.ti,ab.
7. ergocalciferol.ti,ab.
8. toxiferol.ti,ab.
9. retinol.ti,ab.
10. "retinoic acid".ti,ab.
11. Vitamin A/
12. Vitamin B 12/
13. Vitamin D/
14. Vitamin E/
15. "beta-carotene".ti,ab.
16. "alpha-carotene".ti,ab.
17. "gamma-carotene".ti,ab.
18. "beta-cryptoanthin".ti,ab.
19. thiamine.ti,ab.
20. riboflavin.ti,ab.
21. niacin.ti,ab.
22. nicotinamide.ti,ab.
23. pantothenic.ti,ab.
24. pyridoxine.ti,ab.
25. pyridoxal.ti,ab.
26. pyridoxamine.ti,ab.
27. biotin.ti,ab.
28. "folic acid".ti,ab.
29. Folic Acid/
30. cyanocobalamin.ti,ab.
31. methylcobalamin.ti,ab.
32. "l-ascorbic acid".ti,ab.
33. "ascorbic acid".ti,ab.
34. ascorbate.ti,ab.
35. Ascorbic Acid/
36. phylloquinone.ti,ab.
37. phytomeadione.ti,ab.
38. phytonadine.ti,ab.
39. mineral*.ti,ab.
40. multivitamin*.ti,ab.
41. "diet* supplement*".ti,ab.
42. calcium.ti,ab.
43. Calcium/
44. iron.ti,ab.
45. zinc.ti,ab.
46. sodium.ti,ab.
47. potassium.ti,ab.
48. phosphorus.ti,ab.
49. magnesium.ti,ab.
50. chloride.ti,ab.
51. sulphur.ti,ab.
52. mangansese.ti,ab.
53. cobalt.ti,ab.
54. selenium.ti,ab.
55. copper.ti,ab.
56. iodine.ti,ab.
57. fluoride.ti,ab.
Dec 2014: 1320
Jul 2015: 53
Mar 2016: 111
Aug 2016: 103
Mar 2017: 166
Jan 2018: 120
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58. or/1-57
59. *Aging/
60. Aged/
61. "Aged, 80 and over"/
62. Middle Aged/
63. Age Factors/
64. "mild cognitive impairment".ti,ab.
65. Mild Cognitive Impairment/
66. MCI.ti,ab.
67. AAMI.ti,ab.
68. ACMI.ti,ab.
69. ARCD.ti,ab.
70. CIND.ti,ab.
71. (nMCI or aMCI or mMCI or MCIa).ti,ab.
72. "old* adults".ti,ab.
73. elderly.ti,ab.
74. "old* age*".ti,ab.
75. "middle age*".ti,ab.
76. seniors.ti,ab.
77. "senior citizens".ti,ab.
78. "community dwelling".ti,ab.
79. pensioners.ti,ab.
80. "aged sample".ti,ab.
81. "aged population".ti,ab.
82. or/59-81
83. 58 and 82
84. *Cognition/
85. *Cognition Disorders/
86. Memory/
87. Memory Disorders/
88. (cognit* adj3 (func* or declin* or reduc* or impair* or improve* or deficit* or progress*
or perform* or abilit*)).ti,ab.
89. "mental perform*".ti,ab.
90. memory.ti,ab.
91. "executive function*".ti,ab.
92. Executive Function/
93. Attention/
94. (speed adj2 processing).ti,ab.
95. "episodic memory".ti,ab.
96. Memory, Episodic/
97. or/84-96
98. 83 and 97
99. randomized controlled trial.pt.
100. controlled clinical trial.pt.
101. randomized.ab.
102. placebo.ab.
103. drug therapy.fs.
104. randomly.ab.
105. trial.ab.
106. groups.ab.
107. or/99-106
108. exp Animals/ not humans.sh.
109. 107 not 108
110. 98 and 109 [all results]
111. *Vitamins/
112. *Cognition/
113. "Aged, 80 and over"/ or Aged/ or Middle Aged/
114. Mild Cognitive Impairment/
115. "mild cognitive impairment".ti,ab.
116. 113 or 114 or 115
117. 111 and 112 and 116
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118. 99 or 100
119. 117 and 118 [results sent directly to author team]
120. 110 not 119 [results minus those sent directly to author team. These results will be
screened by the 'crowd']
Embase
1974 - 24 January
2018 (Ovid SP)
(Date of most re-
cent search: 25
January 2018)
1. exp *vitamin/
2. exp *mineral/
3. exp diet supplementation/
4. calcium/
5. vitamin*.ti,ab.
6. mineral*.ti,ab.
7. cholecalciferol.ti,ab.
8. ergocalciferol.ti,ab.
9. toxiferol.ti,ab.
10. retinol.ti,ab.
11. retinal.ti,ab.
12. "retinoic acid".ti,ab.
13. vitamin D/
14. vitamin B complex/ or vitamin B group/
15. vitamin D/
16. vitamin K epoxide reductase/ or vitamin K group/
17. colecalciferol/ or calcitriol/ or calcitriol derivative/
18. ascorbic acid/
19. vitamin supplementation/
20. "beta-carotene".ti,ab.
21. beta carotene/
22. "alpha-carotene".ti,ab.
23. alpha carotene/
24. "gamma-carotene".ti,ab.
25. gamma carotene/
26. "beta-cryptoanthin".ti,ab.
27. thiamine.ti,ab.
28. thiamine/
29. riboflavin.ti,ab.
30. riboflavin/
31. niacin.ti,ab.
Dec 2014: 1275
Jul 2015: 114
Mar 2016: 184
Aug 2016: 94
Mar 2017: 257
Jan 2018: 250
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32. nicotinic acid/
33. nicotinamide.ti,ab.
34. pantothenic.ti,ab.
35. pyridoxamine.ti,ab.
36. pantothenic acid/
37. pyridoxamine/
38. biotin.ti,ab.
39. biotin/
40. "folic acid".ti,ab.
41. folic acid/
42. cyanocobalamin.ti,ab.
43. cyanocobalamin/
44. methylcobalamin.ti,ab.
45. "l-ascorbic acid".ti,ab.
46. "ascorbic acid".ti,ab.
47. phylloquinone.ti,ab.
48. phytonadine.ti,ab.
49. phytomeadione.ti,ab.
50. multivitamin*.ti,ab.
51. "vitamin* supple*".ti,ab.
52. "diet* supplement*".ti,ab.
53. calcium.ti,ab.
54. iron.ti,ab.
55. iron/
56. zinc.ti,ab.
57. zinc/
58. sodium.ti,ab.
59. sodium/
60. potassium.ti,ab.
61. citrate potassium/ or potassium/ or clavulanate potassium/ or diclofenac potassium/
62. phosphorus.ti,ab.
63. phosphorus/
64. magnesium.ti,ab.
65. magnesium/
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66. chloride.ti,ab.
67. chloride/
68. sulphur.ti,ab.
69. mangansese.ti,ab.
70. cobalt.ti,ab.
71. cobalt/
72. selenium.ti,ab.
73. selenium/
74. copper.ti,ab.
75. copper/
76. iodine.ti,ab.
77. fluoride.ti,ab.
78. fluoride/
79. or/1-78
80. aging/
81. aged/
82. middle aged/
83. mild cognitive impairment/
84. "mild cognitive impairment".ti,ab.
85. MCI.ti,ab.
86. AAMI.ti,ab.
87. ACMI.ti,ab.
88. ARCD.ti,ab.
89. CIND.ti,ab.
90. (nMCI or aMCI or mMCI or MCIa).ti,ab.
91. "middle age*".ti,ab.
92. "old* age*".ti,ab.
93. "old* adults".ti,ab.
94. "community dwelling".ti,ab.
95. "senior citizens".ti,ab.
96. seniors.ti,ab.
97. pensioners.ti,ab.
98. "aged sample".ti,ab.
99. "aged population".ti,ab.
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100. or/80-99
101. exp cognition/
102. cognition disorders/
103. episodic memory/ or memory/
104. memory disorder/
105. dementia/
106. Alzheimer disease/
107. dement*.ti,ab.
108. alzheimer*.ti,ab.
109. cognition.ti,ab.
110. cognitive.ti,ab.
111. or/101-110
112. 79 and 100 and 111
113. randomized controlled trial/
114. controlled clinical trial/
115. placebo.ab.
116. (random* adj2 divide*).ti,ab.
117. (random* adj2 allocate*).ti,ab.
118. trial.ab.
119. "double-blind*".ti,ab.
120. "single blind*".ti,ab.
121. or/113-120
122. 112 and 121
123. *Cognition/
124. exp *vitamin/ or exp *vitamin supplementation/
125. exp *mineral/ or exp *mineral supplementation/
126. (vitamin* or mineral*).ti.
127. 124 or 125 or 126
128. exp *aging/
129. (elderly or "middle age*" or "old* adults" or MCI or "mild cognitive impairment").ti.
130. exp *middle aged/
131. 128 or 129 or 130
132. 123 and 127 and 131
133. 113 or 114
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134. 132 and 133
135. 122 not 134
PsycINFO
1806 - January
week 2, 2018 (Ovid
SP)
(Date of most re-
cent search: 25
January 2018)
1. exp Aging/
2. exp Cognitive Impairment/
3. "cognit* impair*".ti,ab.
4. MCI.ti,ab.
5. AAMI.ti,ab.
6. ACMI.ti,ab.
7. ARCD.ti,ab.
8. CIND.ti,ab.
9. (nMCI or aMCI or mMCI or MCIa).ti,ab.
10. "old* age*".ti,ab.
11. elderly.ti,ab.
12. "middle age*".ti,ab.
13. "old* adults".ti,ab.
14. seniors.ti,ab.
15. "senior citizens".ti,ab.
16. "community dwelling".ti,ab.
17. pensioners.ti,ab.
18. or/1-17
19. exp Cognition/
20. exp Dementia/
21. 19 or 20
22. randomi?ed.ti.
23. (randomly adj2 allocat*).ab.
24. (randomly adj2 divide*).ab.
25. RCT.ti,ab.
26. "double-blind*".ti,ab.
27. "single blind*".ti,ab.
28. "randomi?ed trial".ab.
29. "randomi?ed control* trial".ab.
30. "random allocation".ab.
31. "controlled clinical trial".ti,ab.
32. or/22-31
Dec 2014: 202
Jul 2015: 15
Mar 2016: 10
Aug 2016: 0
Mar 2017: 14
Jan 2018: 9
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33. exp Vitamins/
34. exp Dietary Supplements/
35. vitamin*.ti,ab.
36. mineral*.ti,ab.
37. calcium.ti,ab.
38. Calcium/
39. exp Ascorbic Acid/
40. exp Folic Acid/
41. "folic acid".ti,ab.
42. cholecalciferol.ti,ab.
43. ergocalciferol.ti,ab.
44. toxiferol.ti,ab.
45. retinol.ti,ab.
46. retinal.ti,ab.
47. "retinoic acid".ti,ab.
48. "beta-carotene".ti,ab.
49. "alpha-carotene".ti,ab.
50. "gamma-carotene".ti,ab.
51. "beta-cryptoanthin".ti,ab.
52. thiamine.ti,ab.
53. riboflavin.ti,ab.
54. niacin.ti,ab.
55. nicotinamide.ti,ab.
56. pantothenic.ti,ab.
57. pyridoxine.ti,ab.
58. pyridoxal.ti,ab.
59. pyridoxamine.ti,ab.
60. biotin.ti,ab.
61. "folic acid".ti,ab.
62. cyanocobalamin.ti,ab.
63. methylcobalamin.ti,ab.
64. "l-ascorbic acid".ti,ab.
65. "ascorbic acid".ti,ab.
66. ascorbate.ti,ab.
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67. phylloquinone.ti,ab.
68. phytomeadione.ti,ab.
69. phytonadine.ti,ab.
70. multivitamin*.ti,ab.
71. "diet* supplement*".ti,ab.
72. iron.ti,ab.
73. zinc.ti,ab.
74. sodium.ti,ab.
75. potassium.ti,ab.
76. phosphorus.ti,ab.
77. magnesium.ti,ab.
78. chloride.ti,ab.
79. sulphur.ti,ab.
80. mangansese.ti,ab.
81. cobalt.ti,ab.
82. selenium.ti,ab.
83. copper.ti,ab.
84. iodine.ti,ab.
85. fluoride.ti,ab.
86. 18 or 21
87. or/33-85
88. 86 and 87
89. 32 and 88
90. exp *Vitamins/
91. (vitamin* or mineral*).ti.
92. 90 or 91
93. exp *Cognition/
94. (cognition or cognitive).ti.
95. 93 or 94
96. (elderly or "middle age*" or "old* adults" or MCI or "mild cognitive impairment").ti.
97. 92 and 95 and 96
98. (randomised or randomised or RCT or trial).ti.
99. 97 and 98
100. 89 not 99
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CINAHL (EBSCO-
host)
(Date of most re-
cent search: 25
January 2018)
S1 (MM “Vitamins+")
S2 (MM “Minerals+")
S3 (MH "Dietary Supplements") OR (MH "Dietary Supplementation") OR (MH "Dietary Car-
bohydrates") OR (MH "Dietary Fiber") OR (MH "Sodium, Dietary") OR (MH "Dietary Fats")
OR (MH "Dietary Proteins") OR (MH "Dietary Sucrose”)
S4 TX vitamin*
S5 TX mineral*
S6 TX “diet* supple*”
S7 (MH "Fatty Acids") OR (MH "Fatty Acids, Omega-6") OR (MH "Fatty Acids, Unsaturat-
ed") OR (MH "Trans Fatty Acids") OR (MH "Fatty Acids, Monounsaturated") OR (MH "Fatty
Acids, Saturated") OR (MH "Fatty Acids, Essential”)
S8 TX “fatty acid*”
S9 (MH "Vitamin A”)
S10 (MH "Vitamin B12") OR (MH "Vitamin B Complex") OR (MH "Thiamine") OR (MH "Ri-
boflavin") OR (MH "Pyridoxine") OR (MH “Carnitine")
S11 (MH "Folic Acid”)
S12 (MH "Ascorbic Acid”)
S13 (MH "Vitamin D") OR (MH "Cholecalciferol") OR (MH "Ergocalciferols") OR (MH “Cal-
citriol")
S14 (MH "Vitamin E") OR (MH "Pantothenic Acid”)
S15 (MH "Vitamin K") OR (MH “Osteocalcin")
S16 TX “beta-carotene"
S17 TX “alpha-carotene"
S18 TX thiamine
S19 TX riboflavin
S20 TX niacin
S21 TX pantothenic
S22 TX nicotinamide
S23 TX pyridoxine
S24 TX pyridoxal
S25 TX biotin
S26 (MH “Calcium")
S27 TX calcium
S28 TX iron
S29 (MH “iron”)
S30 (MH “Zinc”)
S31 TX zinc
Dec 2014: 493
Jul 2015: 7
Mar 2016: 35
Aug 2016: 15
Mar 2017: 24
Jan 2018: 23
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S32 (MH “Sodium”)
S33 TX sodium
S34 (MH “Potassium")
S35 TX potassium
S36 (MH “Phosphorus")
S37 TX phosphorus
S38 (MH “Magnesium")
S39 TX magnesium
S40 (MH "Sodium Chloride, Dietary”)
S41 TX chloride
S42 TX sulphur
S43 TX cobalt
S44 TX selenium
S45 TX copper
S46 TX iodine
S47 TX flouride
S48 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR
S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36
OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47
S49 (MH “Aging")
S50 (MH "Aged") OR (MH "Aged, 80 and Over”)
S51 (MH "Middle Age”)
S52 TX "Mild Cognitive Impairment”
S53 TX MCI OR AAMI OR ACMI OR ARCD OR CIND
S54 TX nMCI OR aMCI OR mMCI OR MCIa
S55 TX elderly
S56 TX "old* adults”
S57 TX "old* age*”
S58 TX pensioners
S59 TX "community dwelling”
S60 TX seniors
S61 TX "senior citizen*”
S62 TX "age* sample”
S63 TX "age* population”
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S64 S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR
S60 OR S61 OR S62 OR S63
S65 S48 AND S64
S66 (MH "Cognition") OR (MH "Cognition Disorders") OR (MH "Delirium, Dementia,
Amnestic, Cognitive Disorders”)
S67 TX cognition
S68 TX memory
S69 (MH "Memory") OR (MH "Memory Disorders") OR (MH "Memory, Short Term”)
S70 TX "executive function”
S71 TX "cognitive* declin*”
S72 TX "cognitive* improv*”
S73 TX "cognitive deficit*”
S74 TX "mental perform*”
S75 TX dementia
S76 TX alzheimer*
S77 (MH “Dementia+")
S78 S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR
S77
S79 S65 AND S78
S80 (MH "Randomized Controlled Trials”)
S81 AB randomly
S82 AB placebo
S83 AB groups
S84 AB RCT
S85 TX "double blind*”
S86 TX "single blind*”
S87 TX "controlled clinical trial”
S88 TI randomised
S89 TI randomized
S90 S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88
S91 S79 AND S90
ISI Web of Science
(includes: Web of
Science (1945 -
present); BIOSIS
Previews (1926 -
present); MEDLINE
(1950 - present);
("mild cognitive impairment" OR elderly OR "age* subjects" OR "old* adult*" OR "middle
age*" OR MCI) AND TOPIC: ("randomly allocated" OR "random allocation" OR randomised
OR randomized OR RCT OR "controlled trial" OR "double blind" OR "single blind") AND
TOPIC: (vitamin* OR mineral* OR "diet* suppl*" OR "ascorbic acid" OR "folic acid" OR
iron OR calcium OR sodium OR zinc OR potassium OR magnesium OR cobalt OR copper
OR iodine) AND TOPIC: (cognition OR dementia OR memory OR "executive function" OR
alzheimer*)
Dec 2014: 932
Jul 2015: 34
Mar 2016: 100
Aug 2016: 43
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Journal Citation
Reports); BIOSIS
Previews
(Date of most re-
cent search: 25
January 2018)
Timespan: All years.
Search language = Auto
Mar 2017: 67
Jan 2018: 55
LILACS (BIREME)
(Date of most re-
cent search: 25
January 2018)
cognition OR "mild cognitive impairment" OR elderly OR "aged subjects" OR "older
adults" OR "middle aged" [Words] and randomly OR randomised OR randomized OR RCT
OR "controlled trial" [Words] and vitamin OR vitamins OR mineral OR minerals OR "fatty
acid" OR "folic acid" [Words]
Dec 2014: 28
Jul 2015: 0
Mar 2016: 0
Aug 2016: 1
Mar 2017: 0
Jan 2018: 0
CENTRAL (via
CRSO)
(Date of most re-
cent search: 25
January 2018)
#1 MeSH descriptor: [Aged, 80 and over] explode all trees
#2 MeSH descriptor: [Aged] explode all trees
#3 MeSH descriptor: [Middle Aged] explode all trees
#4 MeSH descriptor: [Mild Cognitive Impairment] explode all trees
#5 "cognit* impair*" or MCI
#6 elderly
#7 "old* adults"
#8 "old* age*"
#9 "old* sample"
#10 senior citizens
#11 pensioners
#12 seniors
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Cognition] explode all trees
#15 MeSH descriptor: [Dementia] explode all trees
#16 cognit*
#17 memory
#18 "executive function*"
#19 processing
#20 "mental perform*"
#21 dement*
#22 alzheimer*
#23 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 MeSH descriptor: [Vitamins] explode all trees
Dec 2014: 395
Jul 2015: 10
Mar 2016: 50
Aug 2016: 48
Mar 2017: 90
Jan 2018: 54
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#25 MeSH descriptor: [Minerals] explode all trees
#26 vitamin*
#27 mineral*
#28 "ascorbic acid"
#29 "folic acid"
#30 MeSH descriptor: [Fatty Acids] explode all trees
#31 zinc or iron or calcium or sodium or potassium or magnesium or cobalt or copper or
selenium or iodine or flouride or chloride
#32 "beta-carotene"
#33 "alpha-carotene"
#34 thiamine
#35 riboflavin
#36 niacin
#37 biotin
#38 pantothenic
#39 nicotinamide
#40 pyridoxal
#41 "diet* suppl*"
#42 #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38
or #39 or #40 or #41
#43 #13 and #23 and #42
Clinicaltrials.gov
(www.clinicaltrial-
s.gov)
(Date of most re-
cent search: 25
January 2018)
In Intervention studies: [intervention] vitamin* OR mineral* OR "diet* suppl*" OR "ascor-
bic acid" OR "folic acid" OR iron OR calcium OR sodium OR zinc OR potassium OR mag-
nesium OR cobalt OR copper OR iodine AND [condition]: cognition OR "mild cognitive im-
pairment" OR elderly OR "aged subjects" OR "older adults" OR "middle aged"
Trial Status: all
Dec 2014: 147
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 6
Jan 2018: 8
ICTRP Search
Portal (http://
apps.who.int/tri-
alsearch) (in-
cludes: Australian
New Zealand Clini-
cal Trials Registry;
ClinicalTrials.gov;
ISRCTN; Chinese
Clinical Trial Reg-
istry; Clinical Tri-
als Registry – In-
dia; Clinical Re-
In Intervention studies: [intervention] vitamin* OR mineral* OR "diet* suppl*" OR "ascor-
bic acid" OR "folic acid" OR iron OR calcium OR sodium OR zinc OR potassium OR mag-
nesium OR cobalt OR copper OR iodine AND [condition]: cognition OR "mild cognitive im-
pairment" OR elderly OR "aged subjects" OR "older adults" OR "middle aged"
Trial Status: all
Dec 2014: 25
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 4
Jan 2018: 2
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search Informa-
tion Service – Re-
public of Korea;
German Clinical
Trials Register;
Iranian Registry
of Clinical Trials;
Japan Primary
Registries Net-
work; Pan African
Clinical Trial Reg-
istry; Sri Lanka
Clinical Trials Reg-
istry; The Nether-
lands National Tri-
al Register)
(Date of most re-
cent search: 25
January 2018)
TOTAL before de-duplication Dec 2014: 5071
Jul 2015: 233
Mar 2016: 496
Aug 2016: 304
Mar 2017: 631
Jan 2018: 522
TOTAL: 7257
TOTAL after de-duplication Dec 2014: 3451
Jul 2015: 200
Mar 2016: 399
Aug 2016: 208
Mar 2017: 522
Jan 2018: 431
TOTAL: 5211
TOTAL after first assessment by the Crowd and CDCIG information specialists Dec 2014: 448
Jul 2015: 81
Mar 2016: 70
Aug 2016: 45
Mar 2017: 43
Jan 2018: 38
TOTAL: 725
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Appendix 3. Dietary intake and recommended daily intake of included vitamins and minerals
 
Vitamin or
mineral
Daily exposure estimate
from food sources, ex-
cluding supplements,
for men and women in
the UK (mg)
(Gregory 1990)
Reference Nutrient Intake (RNI) for adults (= the amount of a nutrient that
is enough to ensure that the needs of nearly all a group (97.5%) are being
met) set by UK Committee on Medical Aspects of Food and Nutrition Policy
(COMA) in 1991
(Food Standards Agency 2003)
Supple-
mentary
doses used
in studies
included in
this review
(mg)
  Mean 95%ile    
Folic acid 0.26 0.49 0.20 0.4 - 5.0
Vitamin
B6
2.0 3.9 1.4 (men), 1.2 (women) 20 - 50
Vitamin
B12
0.0062 0.020 0.0015 0.4 - 1.0
Vitamin C 64 160 40 400
Vitamin E 8.5 (12.69
IU)
18 (26.87
IU)
Requirement varies widely with diet, no fixed level of intake recommended.
COMA concluded that daily intakes of 4mg and 3mg of α-tocopherol equiva-
lents (5.97 IU and 4.48 IU) could be adequate for men and women respective-
ly (Food Standards Agency 2003)
330 - 2000
IU (Inter-
national
Units)
Chromi-
um
0.1
(source
MAFF
1999)
0.17 COMA has set no RNI but suggests intake above 0.025mg/day is adequate for
adults.US National Research Council specify an
Estmated Safe and Adequate Daily Dietary Intake (ESADDI) of 0.05-2.0mg/day
for adults.
1.0
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Vitacog trial, 7 January 2019
Summary
Comment submitted by A David Smith (Department of Pharmacology, University of Oxford)
I have read with interest your Cochrane review and would like to congratulate you and the team on it. You have collected a lot of information
and analysed it carefully. I do, however, have a few concerns - some are general and some relate to how you report the VITACOG trial of
B vitamins.
In general, I do not think it is really valid to combine trials of di%erent durations (from 6 months to 24 months) since any e%ect on cognition
is likely to be time-dependent (e.g. see Fig. 1 in the De Jager paper). Also, in 6 months one is very unlikely to see any cognitive decline in
the placebo group, so no measurable e%ect of treatment can be expected.
Secondly, I am not happy with the use of mean di%erences or SMD. In this way, you are combining measurements of di%erent parameters,
e.g. a change over 6 months or a change over 24 months; trials with di%erent doses of vitamins, etc.. Cognitive outcomes are subject to
many variables and rather than simply analysing the change from baseline to follow-up, a better approach is to examine the e%ect of an
intervention by modelling the score at follow-up controlling for its baseline value and for variables suspected of influencing cognition
(such as age, gender etc.). The model, for example GLM, should take into account the di%erent type of outcome and use the appropriate
distribution. I am not experienced in statistics but I suspect that it is very di%icult, or impossible, to combine data from di%erent trials using
this kind of modelling which may be why you fall back on the MD or SMD approach.
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Regarding VITACOG (De Jager et al 2012):
1. In Table 2 (page 18) and on pages 19 and 44 you say that our report has a high risk of reporting bias because we did not describe results
from all the outcomes listed in the original Protocol. But in real life you have to select in order to produce a paper that fits the requirements
of journals and we state in the paper “Tests reported here are representative of particular cognitive domains important in MCI”. I notice
that you yourselves have been selective in which cognitive tests you include; for example, you did not cite our results on semantic memory
or on CDR, which showed a beneficial e%ect of B vitamins in those with high homocysteine.
2. On page 44 you say that we have a high risk of reporting bias because we reported the results in subgroups with low and high baseline
homocysteine that was not described in the published protocol in PLoS ONE (2010). You are correct: the Protocol we included as a
Supplement of the 2010 paper was that written at the time of applications for regulatory approval and did not have details of the final
analysis plan. On the other hand, we did state that we planned to measure homocysteine at baseline. Implicit here was the concept that
the outcomes would be related to baseline homocysteine and vitamin levels, since this is standard practice in nutritional studies (see a
cardinal principle of nutrition, Figure 2 in the review by Smith & Refsum 2016 (Smith 2016)). In the final agreed Analysis Plan (18.08.2009)
we clearly specified that we would analyse the results according to the baseline levels of homocysteine, but I realise that this was not, at
the time of writing, in the public domain; however, it is now freely available on https://doi.org/10.17605/OSF.IO/VMRZ5
3. Although you cite some of our subgroup analyses based upon baseline homocysteine, you ignored this in your pooled analyses, which
correctly stated that there was no significant e%ect of B vitamins overall in VITACOG. For MMSE, you did not acknowledge that we found a
protective e%ect of B vitamins in those with homocysteine in the top quartile. The major clinical finding in VITACOG is of a protective e%ect
of B vitamins against decline in episodic and semantic memory and a decline in MMSE and IQCODE in those with MCI who have a high
baseline homocysteine. But this is almost lost in your report, due to the use of MD and SMD in the tables, although you describe some of
the findings in your text. But your final paragraph (page 31) seems to question even our positive results:
“Although there was no evidence of overall benefit from the studies included in this review, one study of B vitamins reported a slowing of
brain atrophy in the whole study population and an attempt to replicate this result is needed. The same study reported that there may be
a beneficial e%ect of B vitamins on episodic memory in the subgroup with higher homocysteine levels at baseline. However, the result of a
very large individual patient meta-analysis which found no e%ect of homocysteine-lowering with B vitamins on cognitive ageing in 22,000
older participants without specific cognitive diagnoses at baseline makes this result less promising to pursue.”
This statement refers to a meta-analysis (Clarke et al. 2014) that you correctly state on page 31 is “not directly relevant to a population
with mild cognitive impairment” but you go on to say: “this result does not support the hypotheses that B vitamin supplementation or
homocysteine-lowering are e%ective means to prevent cognitive decline.” You should not have made that conclusion, neither should the
original authors since they were not able to assess cognitive decline in their subjects as 76% of the participants only had a single measure
of cognition. So no cognitive decline over time could be demonstrated in the placebo group. Without that information, there can be no
measurable e%ect of B vitamin treatment. I am unhappy that your final conclusion is so strongly influenced by a flawed interpretation of a
meta-analysis. The standing of the Cochrane reviews is high and your report will be widely believed.
References
Clarke, R., D. Bennett, S. Parish, S. Lewington, M. Skea%, et al. (2014). E%ects of homocysteine lowering with B vitamins on cognitive aging:
meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr 100: 657-666
de Jager, C. A., A. Oulhaj, R. Jacoby, H. Refsum and A. D. Smith (2012). Cognitive and clinical outcomes of homocysteine-lowering B-vitamin
treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 27: 592-600
Smith, A. D. and H. Refsum (2016). Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr 36: 211-239
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Reply
We thank Professor Smith for his interest in our review. We think that some of the comments really relate to systematic reviewing in
general, or more particularly to the validity of meta-analysis as an approach. Di%erences among the studies included in a meta-analysis are
inevitable. In this case, we fully agree that the di%erences highlighted (constituents and doses of intervention, duration of treatment) are
important. As in any SR with meta-analysis, it was a matter of judgement whether di%erences were so great that data should not be pooled
at all. In Cochrane reviews, if data are pooled, despite potentially important di%erences, the methods always include an assessment of
heterogeneity and an investigation of its possible sources. We took the decision to pool data from trials with durations of 6-24 months.
Heterogeneity was low in all our B-vitamin analyses except for overall cognitive function. There was no suggestion from the Forest plots
that ‘positive’ e%ects in longer trials were being disguised by ‘negative’ e%ects in shorter ones. In fact, for overall cognitive function, the
largest e%ect was from the shortest trial (Fan 2017), although we lacked confidence in this result from an open-label study.
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The MD/SMD approach is the standard Cochrane method for estimating a treatment e%ect from continuous data. We would agree that is
not usually possible to construct more complex models across studies without access to individual participant data. As long as the studies
are well-randomised, potentially confounding factors such as age should not invalidate the analysis.
We regret any impression that we were unfair to VITACOG with our rating of high risk of bias in the selective outcome reporting domain
and we understand that space limitations in a journal article may have influenced the selection of outcomes reported. We did look beyond
single journal articles to determine whether all expected outcomes were reported in included studies (e.g. to secondary publications or
results posted on trial registries). However, we have to be consistent in applying the risk of bias tool and in recording a risk if we are unable
to find outcome data, or if the reporting di%ers from the publicly available analysis plan. We recognised the high quality of the VITACOG
trial in our low risk of bias ratings in all other domains.
We agree that our review also selected particular outcomes to report; these were pre-specified in the published review protocol. We did,
in fact, report CDR data from VITACOG – including the data by homocysteine quartile – under our secondary outcome of Clinical global
impression.
We would disagree with the suggestion that our review rather buries the possible e%ect found in VITACOG among patients with higher
homocysteine at baseline. We recognised the importance of this finding to the field and actually amended our review methods from those
in our protocol in order to be able to report it, which we do quite prominently, including it in the Abstract and in the Plain Language
Summary, and making it the basis of our most concrete recommendation for future research.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol, overall cognitive functioning was a secondary outcome. In the review, we have made it a primary outcome. This is because
studies were selected for inclusion if they reported either the incidence of dementia or a continuous cognitive function measure at follow-
up. It was an objective of the review, reflected in the title, to assess both of these as the key outcomes.
ASer the publication of the protocol, we added the exclusion of study populations with severe vitamin or mineral deficiency where the
intervention given could correct these deficiencies. However, we included studies of participants with mild vitamin deficiencies which are
common in the older population.
In the case of studies of B vitamins, we added baseline serum homocysteine level as a potential e%ect modifier and decided to report
e%ects in subgroups distinguished by baseline serum homocysteine.
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